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1. GENERAL INTRODUCTION ON THE LEGAL, ETHICAL 
AND SOCIO-ECONOMIC BASELINE
The health and social services sector is an important, even a 
dominant economic sector in the European Union. In 2000, the 
sector employed more than 15 million people – more than 9% of 
European  employment  –  making  it  a  more  important 
employment sector than retail with 13.0m workers or business 
services  with  13.3m workers.   The gross  value  added  of  the 
health and social services sector amounted to almost 500 billion 
euro – more than 6% of European Union GDP –, topped only by 
business  services  with  513.7  bn  euro.1 Looking  only  at  the 
human health  sub  sector,  for  which  more  detailed  and 
comprehensive  data  are  available,  total  health  expenditure 
accounted for 8% of GDP in the EU-15 in 2000. On a per-capita 
basis,  health  expenditures  in  current  US$2 varied  from high 
values of 2,514 for Luxembourg and 2,422 for Germany to only 
884 in Greece and 862 in Portugal. Furthermore, health is in 
itself a wealth factor for a nation, those who are healthy can 
work  and  contribute  to  the  economy.  In  the  words  of  David 
Byrne when he was European Commissioner for Health:
“Modern economies are built on good health. Their 
competitiveness  increasingly  depends  on  enabling 
their  citizens  to  lead  healthier,  more  productive 
lives. Good health is a key driver of growth. There is 
evidence  that  a  10%  rise  in  life  expectancy  can 
generate up to 0.35% in GDP increase. Put simply,  
health  generates  wealth.  Each health  euro  better 
spent could make a net saving both for individual 
well-being and for EU competitiveness. This is why 
achieving  good  health  must  become an  economic 
priority.”3
1 These are only rough figures due to considerable differences in national statistics on which these data 
are based.
2 Data available only in US$ from the World Bank (from Jan. to Dec. of 2000, the exchange rate changed 
from about 1 USD for 1 € to about 1 US$ for 1.06 €).
3  Press Release  IP/04/934,  Boosting the economy through better health: Commissioner Byrne 
launches reflection process on the future of EU health policy, Date:  15/07/2004
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However, although the figures quoted above are impressive, we 
should recall they are European averages, and hide significant 
variation across the 27 Member States. With the expansion of 
the European Union by ten new Member States in 2004 and two 
new accessions in 2007 as well  as a further three Candidate 
Countries still in waiting, significant disparities between three 
separate  country groups  become apparent.  Whereas three of 
the new Member States Cyprus (888), Malta (807) and Slovenia 
(788) almost reach the expenditure per capita level of Greece 
and Portugal, the latest two New Members Romania (48) and 
Bulgaria (59) fall far below even the low mean value (218) for 
all of these 12 countries, and reach only about 3% of the mean 
value (1,818) for the old Member States. 
It should also be noted that despite its significant role within 
the European economy, the healthcare sector is quite different 
from almost any other economic sector: it is highly regulated 
with  often  little  competition,  being  mostly  characterised  by 
public  sector  actors  financed  from  public  or  quasi-public 
sources such as taxes or public health insurance funds. There is 
strong  pressure  to  reduce  costs  and  improve  economic 
efficiency  in  the  health  sector.  Healthcare  expenditure  is 
expected to continue to rise, yet the already high expenditure 
levels measured as percentage of GDP, quoted above, indicate 
that  the  scope for  further  increase  is  limited.  The scope for 
increase  in  demand  for  more,  better,  safer,  and  timelier 
healthcare, on the other hand, is unlimited. As a consequence, a 
key challenge that healthcare systems are facing is optimising 
the use of resources in order to meet this increasing demand 
within a context of budgetary constraints.
In order to address some of these differences and challenges 
the European Union has used its  funds,  including its  various 
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framework programmes for RTD, to support the development of 
ICT applications in the health sector, much in the same way as 
national funds have targeted the use of ICTs to improve health 
services access, delivery and safety. The overriding goal of all 
these activities  has  been to  contribute  towards  better health 
and  care  across  Member  States,  in  particular  through 
implementation and diffusion of eHealth products and services 
including  support  for  regional,  national  and  trans-European 
eHealth infrastructures. It is expected that this will contribute 
to better  medical  outcomes,  better  quality  of  life  for citizens 
and patients, more efficiency, and improved access.  However, 
the results of the programmes have been mixed at both EU4 and 
national5 level and they have only recently gained in scope and 
relevance for healthcare professionals and citizens. 
If  it  is  accepted  therefore  that  the  healthcare  sector  is  of 
economic importance, and that for the main it operates within 
the  regulated  framework  of  the  public  sector,  it  is  very 
important that regional, national and supranational policies to 
advance the development and implementation of ICT for health 
are  based  on  a  solid  understanding  of  the  economic  and 
regulatory  aspects  of  adopting  the  new  technologies  and 
applications.  Accordingly  in  this  deliverable  we  provide  a 
baseline of key legal, regulatory and economic issues that need 
to be taken into account by policy makers in seeking to support 
a wide adoption of Grid Technology in the healthcare sector. 
Set against  this background we can see that the adoption of 
emerging technologies like Healthgrid to best effect, when this 
4  Cf.  Veli  N.  Stroetmann,  Karl  A.  Stroetmann  with  Stefan  Lilischkis,  edited  by  Data-Bank 
Consulting: IST Impact Study:  Microelectronics & Microsystems, Health,  Mobile Communications - 
Health  Domain  -:  Study  for  the  European  Commission,  Bonn/Milano/Brussels,  November  2004:
ftp://ftp.cordis.lu/pub/ist/docs/about/final_report_part_b_health.pdf
5  For details, see Stroetmann KA, Stroetmann VN: Electronic business in the health and social 
services sector - Key issues, case studies, conclusions. Sector Impact Study No. 10-II. The European e-
Business Market W@tch, Brussels/Bonn, August 2004, available at http://www.ebusiness-watch.org.
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may mean changing established and valued working and clinical 
practices, will also face significant organisational and medico-
cultural challenges.  
However,  the  use  ICTs  in  healthcare  is  a  reality.  ICTs 
applications  are  used  daily  in  surgical  planning,  clinical 
decision support and radiological examination, to name just a 
few examples. Information technology also forms the backbone 
of hospital administration and is beginning to play a significant 
role in community care administration as well.  Most patients 
are now happy to recognise that their healthcare records are 
stored electronically and, to varying degrees, shared within and 
across  healthcare  institutions  so  that  physicians  and  carers 
have  access  to  up-to-date  and  validated  patient  information 
where and when they need it.  Advances in research promise 
also  that  in  the  near  future  more  and  more  citizens  will  be 
ready to make use of and even demand remote monitoring and 
assessment  technologies  to  allow them to  receive  healthcare 
support  at  home,  work  and  play  without  having  to  use  the 
traditional hospital and primary care services.
According to an earlier study, eHealth ICTs such as healthgrids 
are emerging as the new industry,  alongside pharmaceuticals 
and  the  medical  devices  sector,  to  become  the  third  largest 
industry in the European health sector. The study suggested, for 
example,  that  by  2010  spending  on  eHealth  technology  may 
account  for  up  to  5%  of  the  total  health  budget  of  the  25 
Member States from just 1% in 2000 for 15 Member States6. 
Although the enormous double-digit growth would imply are not 
being  realised  at  present,  European  industry  has  every 
opportunity to become a leading global player in this growing 
industry if a wider, more integrated European market can be 
established, supporting their  competitive position in a growing 
6  SIBIS, Benchmarking Highlights 2002: Towards the Information Society in Europe and the US, 
May 2003. See http://www.sibis.org/.
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global  health  ICT  market7.  This,  in  turn,  will  support 
sustainable growth and the creation of new and better jobs. 
For this reason, it is important that well constructed roadmaps 
for  new eHealth  technologies  are  adopted  so  that  necessary 
steps  can  be  taken  along  the  way  to  ensure  not  only  that 
research and technological development will create new tools, 
but  that  the  legal  and  regulatory  framework  is  ready  to 
accommodate them. Similarly, the economic realities into which 
the new tools are designed to fit must be carefully studied in 
order  to  ensure  that  a  maximum  number  of  business  case 
arguments can be made to show the potential contribution to 
both  health  and  wealth  of  using  new  technologies  such  as 
healthgrids. Finally, the organisational realities and dynamics, 
including  change  management  and  training/education  issues, 
need  also  to  be  considered for  a  successful  deployment  and 
diffusion.  Similarly,  the  legal  and  regulatory  issues  must  be 
addressed because one of the key challenges of the organising 
the  health  sector  arises  from  the  fact  that  one  of  the  core 
components of  any healthcare transaction – patient data –  is 
very complex. 
7  See Deloitte and Touche (2003) eHealth: HINE - Health Information Network Europe; 2003 
report.  Considering present  constraints  on  spending in  this  market,  this  is  probably  a  by  far  too 
optimistic estimate. On the other hand, Frost & Sullivan estimates in its 2004 report on The Market for 
Telemedicine in Europe that just this segment will grow till 2010 to about $ 1.8 bn or around 42% per 
annum, an even more optimistic - and in all likelihood totally wrong - prognosis.
FP6­2005­IST­027694 PUBLIC  10 / 96
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, A. 
Dobrev, J. Herveg, V. 
Stroetmann, K. 
Stroetmann, C. Van 
Doosselaere, P. Wilson 
2. LEGAL AND REGULATORY ASPECTS OF 
HEALTHGRIDS
2.1. INTRODUCTION
In any healthcare setting the amount of personal health data 
collected is voluminous, difficult  to collect,  and changes over 
time.  As  medical  technology  has  advanced,  the  process 
‘components’  that  make  up  the  full  continuum of  care  have 
increased  in  number  and  sophistication.  This  presents 
healthcare providers with a continuously increasing amount of 
data and information to work with. It is only logical to favour 
information  management,  sharing  and  re-use  of  data  as  the 
primary purpose of implementing ICT solutions. It is rational to 
expect that not only old models of healthcare will be enhanced 
by the introduction of ICT into the processes, but also that ICT 
will facilitate, even necessitate the creation of completely new 
models of healthcare. Grid technologies are a primary example 
of emerging ICT that facilitates a new model of healthcare and 
in particular of health-related research.
However,  patient  information  and  healthcare  data  in  general 
are protected by the legal and ethical duties of confidentiality to 
which  all  healthcare  providers  are  bound.  If  therefore  the 
European healthcare systems are to be made more accessible, 
safe and sustainable at least in part through the implementation 
of  ICTs  within  healthcare  workflow  and  processes,  then  we 
must carefully study the extent to which the legal regulation of 
handling and processing of medical data are adapted to the use 
of such ICTs.
A  common  factor  among  eHealth  tools  is  that  they  store, 
process,  forward  and  share  data.  Some  of  that  data  is 
administrative,  some  related  to  objects,  such  as  in  radio-
frequency identification based tracking of devices, but a great 
deal  of  the  data  is  the personal  data  of  patients.  Healthcare 
professionals  know they  have  a  duty  of  confidentiality  and a 
duty of care -they want to exercise both fully in order to provide 
a  safe  environment  in  which  patients  are  treated  with  due 
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respect  for  their  privacy.  The  duty  to  provide  care  is 
undoubtedly served by sharing patient records,  providing on-
line  support  to  colleagues  and even giving direct  support  to 
patients in their homes via the internet… but how does it sit 
with the co-existing duty of confidentiality?
In Europe the approach has been, on the whole, less technical 
and  focused  instead  on  traditional  human  rights  values  of 
privacy. As a result of the European Data Protection Directive, 
the  Member  States  of  the  European  Union  have  generally 
adopted  legislation  that  focuses  primarily  on  the  individual’s 
right  to  privacy  and  secondarily  on  the  need  of  medical 
professionals to share healthcare data.
The  purpose  of  this  report  is  to  explore  the  nature  of  the 
European level response to medical privacy through a detailed 
examination of the data protection directive as well  as  other 
relevant legislation. 
However, data privacy is not the only legal issue that should be 
addressed  in  road  mapping  healthgrids.   It  is  also  vitally 
important to assess the extent to which product and services 
liability is adapted to meeting the challenges of healthgrids, as 
well  as  considering  the  wider  legal-economic  issues  such  as 
intellectual property rights.
The three clusters of legal issues addressed in this report were 
developed during WP4’s initial work with WP3 on D3.1, where 
the  technology  baseline  was  drawn.  Based  on  the  various 
milestones or phases set in the technology baseline, and on the 
subsequent work on bottlenecks and roadblocks, it was felt that 
these clusters of issues would most likely create an obstacle to 
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the further development of the technology at its various phases 
were data protection, liability and intellectual property.
This  report  will  accordingly  look  in  detail  at  the  EU  level 
legislation that covers: 
A. Confidentiality and Data Protection
B. Product and Services Liability
C. Intellectual Property Rights
For  each  of  these  three  issues,  a  “Questions  and  Answers” 
session has been drawn to ensure reader-friendliness from as 
wide an audience as possible. Using the Questions and Answers 
form should render these complex issues more discernible and 
understandable  to  a  non-expert  audience,  thus  facilitating 
reactions and comments from a wide community and enabling 
WP4 to take into account the user needs and requirements in 
the next documents to be produced. 
2.2. CONFIDENTIALITY AND DATA PROTECTION
2.2.1.Introduction
The key principles relevant to the processing of personal data 
were first established by the Council  of  Europe,8 and further 
developed in Directive 95/46/CE of the European Union – the 
European  Data  Protection  Directive.9 The  latter  is  the  major 
source of  legislation,  although the Recommendation made by 
the Council of Europe is also of importance for the healthcare 
sector and for the use of grid technology in that sector, since it 
focuses on the field of medical data and scientific research.
The Directive provides a general framework for the protection 
of privacy with respect to the processing of personal data in its 
widest sense. It is important to note here that the Directive is 
8  Convention No. 108 of the Council of Europe for the Protection of Individuals with regard to 
Automatic Processing of Personal Data adopted on 28 January 1997; Recommendation No. R (97) 18 of 
Committee of Ministers to Member States concerning the protection of personal data collected and 
processed for statistical purposes, adopted on 30 September 1997.
9  Directive 95/46/CE of the European Parliament and of the Council of 24 October 1995 on the 
protection of individuals with regard to the processing of personal data and free movement of such 
data, OJ L 281, of 23 November 1995, 31-50.
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based on the privacy of processing of data, not privacy per se. 
Thus, the Directive does not confer any special rights of privacy 
of an individual which might be covered in a Member State’s 
constitution,  but  rather it  provides  rules  about  how personal 
data may be processed so that the processing itself does not 
infringe the privacy of an individual.  Within the terms of the 
Directive a suitable level of privacy is to be afforded to all data 
related  to  a  natural  person, whether  the  context  of  such 
information  is  the  private,  public  or  professional  life  of  the 
individual.  The  Directive  thus  goes  beyond  the  concept  of 
private life and intimate detail.
The primary purpose of the Directive is to allow the free flow of 
personal  data  between  the  Member  States  of  the  European 
Union,  in  order  to  facilitate  the  establishment  and  the 
functioning of the internal market, while its secondary purpose 
is  to protect the fundamental  rights and freedoms of natural 
persons and in particular their right to privacy with respect to 
the processing of their personal data. The protection granted by 
the Directive does, however, go further than the protection of 
the  natural  person’s  intimacy,  i.e.  generally  speaking  the 
protection of each natural person private life. It applies more 
particularly  to  any  sensitive  data  relating to  natural  persons 
such as data concerning health -including mental health.
2.2.2.To  what  data  does  the  data  protection  directive 
apply?
In deciding if the Directive applies to a particular set of data 
one must therefore first ask if the data allow the identification 
of a particular natural person and second if the data are going 
to be processed by someone (a legal  or natural  person).  The 
basic  principle  here  is  that  if  a  piece  of  information  (a 
laboratory result) can be linked to a person either by reasonably 
simple means or even by or with the help of a third party, then 
the  data  are  considered  as  identifiable  and  therefore  in  the 
scope of the Directive. It should be noted that this concept is 
usually construed quite widely. Thus, if the information refers to 
a  group  or  if  it  is  so  complete  or  so  unique  as  to  make  it 
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applicable to only a very small number of people (e.g., disease 
profile, age, gender, postcode, profession all held together) then 
the  data  could  be  classified  as  identifiable  even if  no  actual 
identifier is used.
Given the wide construction it is easy to see that the data contained in 
a healthgrid, even if not identified by a patient’s or a study subject’s 
name, will be covered by the terms of  article 2(a) of the Directive 
which  states  that  the  term  ‘personal  data’  relates  to;  “any 
information  relating  to  an  identified  or  identifiable  natural  person 
(‘data subject’); an identifiable person is one who can be identified,  
directly or indirectly,  in particular by reference to an identification 
number  or  to  one  or  more  factors  specific  to  his  physical,  
physiological, mental, economic, cultural or social identity”.
2.2.3.To whom does the data protection directive apply?
The data protection rules are addressed primarily to the  data 
controller, i.e., the legal name of the person who decides the 
purpose and the means of the processing. This person has the 
legal  duty  to  ensure  that  data  are  handled  appropriately  in 
order to ensure the right level of privacy. The data controller is 
usually a senior staff and who is officially named as the data 
controller  by  organisation’s  governing  body.  Although  the 
controller  is  always  a  natural  (real)  person,  he  does  not 
necessarily have to belong to a formally constituted body. 
2.2.4.What are the main duties of a data controller?
Any personal data that the controller needs to process for the 
purposes  of  his  professional  or  other  activity  must  meet  a 
certain  level  of  quality.  This  means  that  the  controller  must 
comply  with  the  Directive’s  principles  concerning  data 
collection and data processing.
First,  this  means  the  data  may  only  be  collected  for 
specified, explicit and legitimate purpose. In practice that 
will  require the controller to define clearly and precisely the 
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purpose(s)  for  which  the  data  are  to  be  processed.  The 
controller  will  therefore  have  to  notify  the  relevant  national 
authority that he is intending to collect personal data and must 
set out clearly what data will be collected and for what reason. 
The controller should also be able to explain the purpose and 
process of the data collection and handling to the data subject.
Second, the purpose of the processing must be legitimate. 
The  Directive  lists  the  general  conditions  under  which  the 
processing  will  be  presumed  as  legitimate  and  the  national 
legislation  further  defines  what  types  of  data  processing  are 
legitimate. 
We noted earlier that the overarching purpose of the Directive 
is  to protect privacy within the context  of  the growth of  the 
internal market. This means that to be legitimate the interests 
in the data processing must outweigh the interests of the data 
subject in excluding the processing of the data.  Medical data 
processing  is  usually  legitimate  processing  because  the  data 
subject will have a significant interest in her health data being 
shared  with  appropriate  professionals  if  the  sharing  of  the 
health  information  will  allow  better  and  safer  healthcare 
delivery.
Generally a controller may only process personal data for the 
purpose that was given when the data were first collected. In 
some  cases,  the  controller  may  want  to  re-use  the  data  for 
another purpose.  This will  only be legal  if  the secondary use 
falls under the uses covered by the national legislation. In many 
Member States such re-use is permitted if it is for statistical, 
scientific or historical purposes. 
Furthermore, the data collected should be adequate for the 
stated purpose but not excessive. If a researcher collects data 
in order to carry out a specified research project, he may not 
collect other data that are not necessary for the study in hand 
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but  might  be  useful  at  some  later  date.  Once  the  data  are 
collected, the controller must keep them up-to-date for as long 
as they are needed for the specified purpose, but should not 
keep  them  longer  than  necessary,  and  must  render  them 
anonymous or destroy them when the pre-defined purpose of 
processing has been achieved.
If  the  data  are  to  be  processed  by  a  third  party  –  a  data 
processor – this means in practice that the contract between 
the  data  controller  and  the  data  processor  must  include  a 
clause that the data processor shall act only on instruction of 
the data  controller  and that  he is  also legally  responsible  in 
case of any breach of data confidentiality.
The controller also has a duty to ensure that data are stored 
and  processed  securely  by  taking  appropriate  technical  and 
organisational  measures  to  ensure  the  security  and 
confidentiality of person identifiable data.  According to Article 
17 of the Directive, the controller has the obligation to ensure 
the security of the personal data processed, meaning that he 
must ensure that the data are not lost, altered, or accidentally 
destroyed.  In  order  to  achieve  those  two  purposes,  the 
controller  must  implement  appropriate  technical  and 
organisational  measures to  protect  personal  data  against,  for 
instance, accidental or unlawful destruction or accidental loss, 
alteration,  unauthorised  disclosure  or  access,  in  particular 
where the processing involves the transmission of data over a 
network, and against all other unlawful forms of processing.10 In 
other  words,  the  controller  has  to  construct  his  system  to 
render it sufficiently secure for the processing of personal data. 
This might also imply that in a healthcare setting a structural 
reorganisation  of  the  hospital  or  research  institute  is 
undertaken to ensure the confidentiality and the security of the 
data processed. This might include the appointment of a data 
protection officer in charge of the data protection issues. On the 
other hand, technical measures could include restricted access 
10  Directive 95/46/CE, art. 17, 1, § 1.
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to the databases to authorised persons and the utilisation of 
software protecting the system against viruses or hacking. 
Processing nominative or identifiable data in medical research grid 
would  be  legitimate  if  research  were  given  as  the  purpose  of  the 
processing  at  the  time  of  collection.  However,  the  controller  of  a 
healthgrid must ensure that nominative or identifiable data are not 
kept for longer than necessary for the originally defined purpose -in a 
longitudinal of multi-purpose research study it will therefore usually 
be  necessary  to  keep  the data  in  an anonymous or  pseudonymous 
form.  Furthermore  where  nominative  or  identifiable data  are 
stored reasonable steps must be taken to hide the true identity of a 
data subject. Given that the nature of grids is to share the data – often 
over national boundaries – the steps taken to protect the data must be 
commensurate  with  the  processing  technology.  In  other  words, 
because  a  grid  is  a  hi-tech  application,  state  of  the  art  security 
technology must be used to protect that data stored and processed in 
the grid.
2.2.5.Are all personal data treated in the same way by the 
Directive?
A general principle provides that the level of protection offered 
by  the  Directive  to  personal  data  depends  not  on  the 
information content, but on the purpose of the data processing. 
In  other  words,  the  potential  or  actual  infringement  for  the 
fundamental rights and freedoms of the data subject of privacy 
and autonomy will be assessed on the basis of the purpose of 
the processing of personal data. 
However,  a  key  indicator  remains  in  the  nature  of  the  data. 
Some data are considered as sensitive and in need of special 
protection. This is the case of personal data revealing racial or 
ethnic  origin,  political  opinions,  religious  or  philosophical 
beliefs,  trade-union  membership,  as  well  as  data  concerning 
health or sex life and judicial data. For these data the protection 
depends on the content of the information and on the purpose 
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of  the  data  processing.  Therefore  article  8  of  the  Directive 
prohibits the processing of medical and other sensitive data. 
The  ban,  however,  is  not  absolute.  The  Directive  sets  out  a 
number  of  cases  in  which  the  collection  and  processing  of 
medical  data  may  be  legitimate.  As  a  result  the  national 
legislation  of  the  Member  States  will  allow  processing  of 
medical data if:
• The controller has obtained the explicit informed consent 
of the data subject; or
• If the data are collected to protect the vital interest of the 
data subject or of another person when the data subject is 
physically or legally incapable of giving his consent; or
• The  data  are  collected  for  the  purposes  of  preventive 
medicine,  medical  diagnosis,  the  provision  of  care  or 
treatment or the management of healthcare services and 
if the data are processed by a health professional subject 
to  the  obligation  of  professional  secrecy  or  by  another 
person also subject to an equivalent obligation of secrecy. 
The Directive provides the possibility for the Member States to 
add exemptions for reasons of substantial public interest that 
could  be  subject  to  further  specific  safeguards,  such  as  the 
authorisation  of  the  national  supervisory  authority.  Thus,  a 
national  transposition  of  the  Directive  might  allow  for  the 
adoption of a national exemption for scientific research or for 
social security reason. 
According to the exemptions to article 8, as listed in its paragraphs 
and  sub  paragraphs,  a  healthgrid  containing nominative  or 
identifiable health data  will  be legal  in terms of  data protection 
only if the explicit consent of the data subject was obtained before 
the data were collected. If this did not happen then the data in the 
grid are handled by a medical doctor AND the purpose of the grid is 
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the further preventive medicine, medical diagnosis, the provision of 
care or treatment or the management of health-care services. If the 
person  handling  the  data  is  not  a  medical  doctor  but  a  research 
scientist he or she will have to be contractually bound in his or her 
employment contract to maintain the confidentiality of the data.  The 
only case in which these criteria need not be met is where the 
Member State in question has passed specific legislation which 
provides different terms for data collection and processing for 
the purposes of medical, scientific or historical research.
2.2.6.What  rights  does  the  Directive  give  to  the  data 
subject?
The general purpose of the Directive is to facilitate sharing of 
data in the context of the internal market while allowing the 
data  subject  to  retain  appropriate  control  over  the  data. 
Accordingly  the  Directive  requires  that  data  subjects  have 
access  to  information  about  the  type  of  data  held  and  the 
purpose for which it is processed and further the data subject 
must  be allowed to  have  any  errors  in  the data  rectified or, 
under some conditions, to object to the processing and have it 
stopped.
A  distinction  is  made  between  cases  where  the  data  are 
collected  directly  from the  data  subject  and  where  they  are 
collected indirectly. If the data are collected directly from the 
data subject the controller must provide at least identity (name, 
address, denomination or trade name, etc.) and a description of 
the  purposes  of  the  processing.  These  purposes  have  to  be 
specified and explicit, which means that a precise description of 
the  scientific  or  the  statistical  project  must  be  given.  The 
processing of sensitive data or medical data normally requires 
the  provision  of  further  information.  Guidelines  provide,  for 
example,  that  in  case  of  genetic  analysis,  the  data  subject 
should  be  informed about  the  objectives  of  the  analysis  and 
about the possibility of unexpected findings.11 
11  See Recommendation No. R (97) 5 of the Committee of Ministers to Member States on the protection 
of medical data adopted on 13 February 1997.
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When personal data have not been obtained directly from the 
data subject, the controller should, before considering the way 
of processing these personal data or the right time to inform the 
data subject, assess whether they comply with the requirements 
for re-use of data.12 
Moreover, the duty of information does not apply when data are 
indirectly collected for processing for statistical purposes or for 
the purposes of historical or scientific research, if the provision 
of  such  information  is  impossible  or  would  involve  a 
disproportionate effort. 
All data subjects have the right to request specific information 
about  their  own  personal  data  that  are  processed  by  the 
controller.  Moreover,  where medical  data are processed, data 
subjects  may  ask  a  healthcare  professional  to  exercise  their 
access  right.  Upon  request,  the  controller  will  then  have  to 
provide the data subjects with information such as whether or 
not data processing of data relating to them is taking place. He 
will  also  have  to  inform  them  about  the  purpose  of  the 
processing,  the  categories  of  data  and  the  data  being 
processed, the recipients or categories of recipients to whom 
the data are disclosed and the source of the data. However, the 
Directive allows Member States to exempt the controller from 
respecting the data subject’s access right where the purpose of 
the processing is scientific research, or when data are kept in 
personal form for a period which does not exceed the period 
necessary to create statistics.  The Directive, however, subjects 
the granting of  that exemption to the condition that  there is 
clearly no risk of breach of the data subject’s privacy. Moreover, 
12  See paragraph 2.2. supra.
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data may not be used in order to take measures or decisions 
regarding any particular individual.
Under the Directive, a data subject has the right to ask for data 
to be corrected, erased or blocked where their processing does 
not  comply  with  the  provisions  of  the  Directive.13 This  is 
particularly  the  case  where  personal  data  are  incomplete  or 
inaccurate. This right means that the controller must correct, 
erase or block the data as required by the data subject, in a 
reasonable period. Blocked data cannot further be processed, 
used, or communicated without the data subject’s consent. In 
addition, if the controller has disclosed the data to third parties, 
he has to notify them about any correction, erasure or blocking 
carried out. This notification of correction, erasure or blocking 
of  data  does  not  have  to  be  performed  if  it  proves  to  be 
impossible or involves a disproportionate effort.14 
The Directive allows Member States to exempt the controller 
from  the  obligation  to  respect  the  data  subject’s  right  of 
correction  in  case  of  processing  for  purposes  of  scientific 
research, or when data are kept in personal form for a period 
which  does  not  exceed  the  period  necessary  for  the  sole 
purpose  of  creating  statistics.15 Furthermore  the  Directive 
provides that  the data  subject  has  the right  to  object  to the 
processing of his data. When there is a legitimate objection to 
the data processing, the controller may  no longer process the 
concerned data or communicate them to recipients,  and must 
ensure they are erased.16
The  controller  of  a  healthgrid  must  therefore  first  ensure  that  he 
knows from whom the data is being collected, because if it is being 
collected directly from a data subject he must inform the data subject 
about the purpose of the collection. This may be implicit information if 
13  Directive 95/46/CE, art. 12(b).
14  Directive 95/46/CE, art. 12 (c).
15  Directive 95/46/CE, art.  13, 2.
16 Further to this the Council  of Europe has recommended in  Recommendation No. R (83) 10 on the 
protection of personal data used for scientific research and statistics, that where processing is conducted 
for scientific or statistical reasons, the data subject may withdraw his collaboration. This is however not 
binding upon Member States, but  is considered as good research practice.
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the controller is the data subject’s treating doctor, but in the case of a 
scientist collecting data for research purposed directly from the data 
subject the purpose should be explicitly stated. If the data are being 
drawn  from  existing  records  the  data  subject  should  be  informed 
about the research if it is not unduly difficult or costly to do so. Next 
he must ensure that he can grant access to the data subject to his 
data if he requests it, unless national legislation provides that this is 
not necessary. If any of the provisions safeguarding the data subject’s 
interests are not complied with, the data subject would have the right 
to demand that his data are withdrawn from a study or database. It is 
therefore very much in the scientist’s interests to ensure he complies 
with the legislation because not only might national legislation levy a 
fine for non-compliance but also a data subject could severely disrupt 
a study if he discovered that data were unlawfully held and decided to 
exercise  his  right  to  have  them  erased.  The  scientist  should  also 
ensure that the data collected are accurate, because if they are not 
the data subject has a right to demand they be corrected and, if this is 
not possible, that they be erased.
2.2.7.What  are  the  implications  for  Cross-Border  Data 
Sharing? 
Healthgrids  provide  doctors,  researchers  and  health  system 
planners the opportunity to support areas of healthcare such as 
medical imaging and image processing; modelling the human 
body  for  therapy  planning;  pharmaceutical  research  and 
development;  epidemiological  studies;  and  genomic  research 
and  treatment  development.  However,  in  order  to  be  truly 
effective  such  grid  applications  must  draw  together  huge 
amounts of data from disparately located computers – which of 
course implies data sharing across jurisdictions and the sharing 
of responsibilities by a range of different data controllers.
National legislations of the different EU Member States are now for 
the most part harmonised, and the transfers of personal data between 
these  Member  States  should  not  create  a  problem.  Thus,  a  data 
controller of a healthgrid established on the territory of one Member 
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State can, in theory, be sure that in transferring the data he processed 
to another controller established in another Member State, that these 
data  would  be  correctly  protected  as  the  second  Member  State 
provides for the same level of protection of personal data as his own.
This would be the case if all Member States had transposed the 
Directive in the same way.  But differences are already to be 
found  in  the  Member  States’  legislations  as  regards  the 
definitions of key concepts of the Directive such as ‘personal 
data’, ‘processing’ or ‘controller’. Moreover, the Directive itself 
allows  the  Member  States  to  “adopt  legislative  measures  to 
restrict the scope of the obligations and rights provided for in 
Articles 6 (1),  10, 11 (1),  12 and 21 when such a restriction 





There  might  thus  be  differences  in  the  level  of  protection 
granted to personal data between the EU Member States, which 
might be a problem for the implementation of the healthgrid 
technology  on  the  whole  territory  of  the  European  Union. 
However,  it  is  important  to  note  that  even  if  there  are 
differences in the levels of protection of personal data between 
the Member States, these differences are of minor importance, 
as the implementation of the Directive already ensures a high 
level of protection for personal data. These differences in the 
levels  of  protection  of  personal  data  between  the  Member 
States  cannot  even  constitute  barriers  to  data  transfers  as 
Article 1, paragraph 2 of the Directive prescribes:
“Member States shall neither restrict nor prohibit the free flow 
of personal data between Member States for reasons connected 
with  the  protection  afforded  under  paragraph  1  (i.e.  the 
protection of data subjects’ fundamental rights and freedoms)”.
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This is not always the case as regards the transfer of personal 
data  towards  other  countries  located  outside  the  European 
Union  and  the  European  Economic  Area  (EEA),  where  data 
protection is governed by specific conditions17 that need to be 
met in addition to the requirements for the communication of 
personal  data  to  third  parties  as  analysed  above.  If  the 
destination country is not in the European Union, the general 
rule  is  that  the  controller  should  refrain  from  transferring 
personal  data  to  a  recipient  located  in  non-EEA  countries. 
However, the Directive provides that if the data subject gives 
his consent unambiguously to the proposed transfer or if  the 
transfer is necessary for the performance of a contract between 
the data subject and the controller (as might be the case for 
healthcare) or if the transfer is necessary for the conclusion or 
performance of a contract concluded in the interest of the data 
subject between the controller and a third party (as might be 
the case in medical research undertaken for a specific patient 
or group of patients) or if the transfer is necessary in order to 
protect the vital interests of the data subject, such a transfer 
can take place towards countries located outside the European 
Union and the EEA.
Moreover,  the  Directive  states  that  Member  States  may 
authorise a transfer or a set of transfers of personal data to a 
third  country  that  does  not  ensure  an  adequate  level  of 
protection  of  personal  data,  where  the  controller  adduces 
adequate  safeguards  through appropriate  contractual  clauses 
between the sender and the recipient of the personal data. In 
this  context,  the  European  Commission  proposes  standard 
contractual clauses that ensure an adequate level of protection 
of transferred personal data. 
However, the European Directive does not set specific conditions for the transfer of 
medical data to non­EU (and non­EEA) countries, but the Recommendation No. R 
17  Directive 95/46/CE, articles 25 and 26.
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Furthermore, some countries, such as Argentina, Isle of Man, 
Guernsey  and  Switzerland,  have  been  recognised  by  the 
European  Commission  as  ensuring  an  adequate  level  of 
protection.  This  means  that  the  European  Commission  has 
decided  that  these  countries  have  a  level  of  protection  of 
personal data in some way equivalent to the one available in the 
Member States of the European Union. The transfer of data to 
companies or other legal entities located on the territory of the 
United States that adhere to the US Department of Commerce’s 
Safe Harbour Privacy Principles is also allowed. The European 
Commission moreover allows the transfer of personal data to 
recipients  located  on  the  territory  of  Canada,  provided  that 
these  recipients  are  subject  to  the  Canadian  Personal 
Information  Protection  and  Electronic  Documents  Act  (also 
called the ‘PIPED Act’). 
2.2.8.Are there special rules for processing and sharing 
genetic data?
The European Directive does not contain all the rules relating 
to  the  processing  of  medical  or  genetic  data.  Some  specific 
rules  relating  to  the  processing  of  medical  data  have  been 
proposed by the Council of Europe within Recommendation No. 
R (97) 5 of the Committee of Ministers to Member States on the 
protection of  medical  data,  adopted on 13 February 1997.  It 
should  be  noted  that  these  are  guidelines  and  not  legally 
binding.
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The  Recommendation  provides  that  only  healthcare 
professionals  or  individuals  or  bodies  working  on  behalf  of 
those healthcare professionals should carry out the processing 
of medical data. Those individuals or bodies should be subject 
to  confidentiality  rules  equivalent  to  those  incumbent  on 
healthcare  professionals.18 Moreover  medical  data  must 
normally be obtained directly from the data subject,  but it  is 
possible to obtain such data from other sources of information 
when some conditions are met (as provided for in the Directive). 
Finally,  medical  data  should  not  be  communicated  to  third 
parties  unless  some  conditions  are  met. As  regards  the 
processing of genetic data, the Recommendation No. R (97) 5 
establishes that genetic data that are collected and processed 
for  preventive  treatment,  diagnosis  or  treatment  of  the  data 
subject or for scientific research, should only be used for those 
purposes. 
Many healthgrid initiatives will be established to process and share 
genetic data. It should be noted that for these data no specific rules 
exist at EU legal level and that therefore the normal rules described 
above will apply. However, the Council of Europe’s Recommendation 
No. R (97) 5 provides guidelines that state that genetic data that are 
collected  and  processed  for  preventive  treatment,  diagnosis  or 
treatment of the data subject or for scientific research, should only be 
used for those purposes. So, a healthgrid controller using genetic data 
should,  as  a  matter  of  good  practice,  be  aware  of  the 
recommendations and should be able to comply with them.
18  This requirement is equivalent to the one contained in Article 8, 3 of the European Directive which 
provides that  ‘Paragraph 1 shall not apply where processing of data is required for the purposes of  
preventive medicine,  medical  diagnosis,  the provision  of  care or treatment or the management of  
health-care services, where those data are processed by a health professional subject under national  
law or rules established by national competent bodies to the obligation of professional secrecy or by  
another person also subject to an equivalent obligation of secrecy”.
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It is also important to underline that other specific rules exist 
for the processing of other person-identifying data,  when the 
purpose  of  the  processing  is  scientific  or  statistical. 
Recommendation No. R (83) 10 of the Committee of Ministers 
to Member States on the protection of personal data used for 
scientific  research  and  statistics,  adopted  on  23  September 
1983, proposes different principles for the processing of these 
data for research or statistics purposes.  It  recommends that, 
where possible, research should be undertaken with anonymous 
data;  only  if  using  anonymous  data  renders  the  research 
impossible, should person identifiable data be used. 
2.2.9.Are  there  any  legal  rules  concerning  network 
security?
The  discussion  above  on  the  Data  Protection  Directive  has 
clarified that the data subject has rights, including a right to 
access  the  data.  The  networks  hosting  data  processing 
therefore have to be suitably adapted to be able to ensure that 
the data are kept secure and that, where appropriate, they can 
be corrected. 
The  confidentiality  and  security  requirements  for  data 
processing,  whether  in  a  Grid  or  any  other  computer 
architecture, are mainly regulated in the 8th section of Directive 
95/46/EC. 
Article  16  of  the  Directive  provides  that  “any  person  acting 
under  the  authority  of  the  controller  or  of  the  processor 
including  the  processor  himself,  who  has  access  to  personal  
data  must  not process  them except  on instructions from the 
controller, unless he is required to do so by law”. The controller 
must therefore ensure the confidentiality of the personal data, 
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processed, meaning   that  he must   ensure  that   the  data   are not   lost,   altered, or 
accidentally destroyed.
In  order  to  meet  the  obligations  of  articles  16  and  17  the 
controller  must  implement  appropriate  technical  and 
organisational  measures to  protect  personal  data  against,  for 
instance, accidental or unlawful destruction or accidental loss, 
alteration,  unauthorised  disclosure  or  access,  in  particular 
where the processing involves the transmission of data over a 
network, and against all other unlawful forms of processing.19 In 
other  words,  the  controller  has  to  construct  his  system  to 
render it sufficiently secure for the processing of personal data. 
He should also ensure that the organisational structure of his 
company  is  adequate  to  ensure  the  confidentiality  and  the 
security of the data processed.20
This  means  that  the  protection  of  the  data  enclosed  in  the 
system has an impact on the system itself. The data controller 
must  collaborate  with  the  network  controller  to  fulfil  the 
confidentiality  and  security  requirements.  The  infrastructure 
must  be  confidential  to  protect  the  rights  of  the  patients.  It 
must also be secure and stable enough to prevent any damage 
to the data collected, processed and stored.  According to the 
law,21 the appropriate level of protection to ensure depends of 
the state of the art, the cost of the system’s implementation, the 
risks represented by the processing, and the nature of the data 
19  Directive 95/46/CE, art. 17, 1, § 1.
20 An example of an organisational measure could be the appointment of a data protection officer in 
charge of the data protection issues. On the other hand, technical measures could include restricted 
access  to the databases to  authorised persons and the utilisation of  software protecting the system 
against viruses or hacking.
21  Directive 95/46/CE, art. 17, 1, § 2.
FP6­2005­IST­027694 PUBLIC  29 / 96
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, A. 
Dobrev, J. Herveg, V. 
Stroetmann, K. 
Stroetmann, C. Van 
Doosselaere, P. Wilson 
to  be  protected (for  instance  sensitive  data,  like  health  data 
require a higher level of protection).
In a healthgrid, a number of data controllers and data processors will 
work  together.  In  such  circumstances,  the  data  controllers  must 
reinforce  security  and  confidentiality  measures  because  the 
information  collected  are  disseminated  to  another  person  who will 
process it.  Each original data controller (i.e., the original collection 
point)  should  then  ensure  that  the  processors  provide  sufficient 
guarantees  on  technical  security  measures  and  on  organisational 
measures governing the processing to be carried out and on the fact 
that  he  will  comply  with  those  measures.  The  European  Directive 
requires that in such cases the processing should be governed by a 
contract or by a legal act binding the processor to the controller and 
stipulating  in  particular  that  the  processor  shall  only  act  on  the 
instructions of the controller and that he should be responsible for 
taking all appropriate technical and organisational measures.
2.2.10.Conclusion
The discussion  of  the basic  concepts  and duties  of  the  Data 
Protection Directive and its impact on healthgrids shows that 
when  healthgrids  are  used  for  treating  patients  or  planning 
care the requirements of the legislation provide that so long as 
the data subject has consented or the data are collected and 
processed by medical professionals the balance of rights weighs 
in  favour  of  data  collection  -that  is,  it  is  assumed  that  the 
patient’s general interest in obtaining treatment or advancing 
medical care outweighs his interests in privacy. 
However, most of the newly developed health grid applications 
that  exist  and  are  currently  running  are  for  longer  term 
purposes  –  that  is,  research,  preventative  medicine  or 
healthcare  planning  –  and  are  not  controlled  by  medical 
professionals but rather by research scientists.  Where this is 
the case, Member States have the possibility to enact specific 
legislation covering specific tools such as healthgrids in order 
to exempt the scientist using running healthgrids from some of 
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the more onerous duties of the Directive. Member States could, 
for example adopt specific legislation to encourage the linking 
of diagnosis specific databases across a region or state in order 
to support research into a given disease. However, no Member 
States has specifically addressed legislation to this particular 
issue and so healthgrids drawing the data and data processing 
power of many hospitals together are burdened with heavy data 
protection  requirements  which  could  deter  scientists  from 
adopting  healthgrid  technology  and  using  its  enhanced 
computational and data acquisition power.
Perhaps more significantly little attention has been paid to the 
specific needs of data sharing for healthgrids across European 
borders and outside the Union. If healthgrids are really to grow 
to their full potential and deliver their promises,  adjustments 
must be made to national and supranational legislations to re-
assure would-be healthgrid users that it is legal to share health 
related  data  using  grid  technology.  This  in  turn  implies  the 
development  and  adoption  of  robust  guidelines  developed 
specifically  for  the  healthgrid  context  which  address  the 
balancing  of  interests  between  an  individual’s  privacy  and 
medical advancement.
2.3. PRODUCT AND SERVICES LIABILITY
2.3.1.Introduction
As we  saw in  the  first  part  of  this  analysis,  implementing  a 
healthgrid generally implies the processing of patients’ health 
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personal data,  which in turn implies risks for patients’ rights 
and  liberties.  Implementing  a  healthgrid  and  using  it  in  a 
hospital for instance, implies other risks for patients. Indeed in 
case of malfunctioning of the system or of problem in the supply 
of  services,  patients  could  be  harmed.  It  is  possible  that  a 
malfunctioning healthgrid could cause a wrong decision to be 
made and thus injury or harm to be caused to patients. Yet at 
present, there is no specific European legislation covering such 
eventualities.  In order to understand the legal  liabilities of a 
healthgrid controller  as  they are provided for  at  a  European 
level we have to look at general product and services liability 
legislation. 
In the health sector legal aspects of medical liability are most 
commonly regulated at the health provider-patient level. Thus 
when  a  patient  is  the  victim  of  medical  negligence  or  of  a 
medical error, the legal questions are usually solved on a simple 
basis of professional liability. In general, this is an issue solved 
through national law, based in most European Countries in a 
no-fault liability rule in torts – that is, if a patient is harmed, 
he is  compensated regardless of  the intent of the healthcare 
practitioner. This is not,  however the case in all  EU Member 
States.  In some cases,  there may of  course be allegations of 
criminal negligence or even criminal intent, in which case the 
healthcare professional might face prosecution.
However, not all doctor-patient relationships are simple. In fact, 
for most medical treatments delivered in hospital or specialist 
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care  settings,  a  number  of  healthcare  practitioners  will  be 
involved in the care of the patient: clinical specialists, nurses, 
radiologists, radiographers etc. Determining the responsibilities 
for each one has become difficult. Who should be regarded as 
liable in the event of problems? The doctor? All the members of 
the medical team in charge of the patient? The hospital? 
In the case of a medical establishment operating a healthgrid 
and  perhaps  making  diagnostic  decisions  based  on  the 
information provided in  the Grid,  the  problems become even 
more complex.  Even if at first the medical  liability has to be 
considered  in  the  relationship  between  the  patient  and  the 
healthcare practitioner,22 the establishment of the person to be 
held responsible for a specific damage can be problematic when 
taking into account the number of intermediaries participating 
to a healthgrid and the complexity of such a system involving 
different  actors  such  as  doctors,  specialists,  hospitals, 
pharmaceutical  companies,  data  controllers  and  processors, 
technicians, etc., often located in different countries.23
As noted above there are no specific liability rules applicable to 
products  and  services  possibly  supplied  by  the  healthgrid 
systems or composing them. Such interaction will therefore be 
assessed, in terms of legal liability, on a general principle that 
products and services provided to consumers must comply with 
a certain level of quality.24 
22  The principle is that a patient victim of a medical negligence or error will at first bring proceedings 
against his doctor.  The generalist is thus the front line in case of medical damages caused to a patient.
23 As  stated by senior  researcher Jean Herveg in the report  Legally  e-Health:  Product  Liability  and 
Consumer Protection  (to be published), in the healthcare practice, the patient is nowadays frequently 
aware of the different intermediaries in charge of his file. In case of damage, he could then logically bring 
proceedings  against  them  rather  than  against  his  doctor.  Difficulties  could  then  occur  from  the 
differences in the way their responsibility is been engaged. On the other hand, the patient is more and 
more in charge of his health, without the intervention of a healthcare practitioner. Thus, beyond the 
articulation of the different healthcare practitioners’ liability, there are situations where the patient is no 
more taken in charge by a healthcare practitioner. Under these circumstances, the patient stands alone 
against  the  pharmaceutical  companies  or  the  medical  devices  companies  which  might  be  subject  of 
different rules regulating their liability. It might thus be impossible for the patient to find an interlocutor 
and to obtain compensation for the damage caused to him.
24  This principle applies mutatis mutandis to business-to-business relations. See infra.
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At a European level, a range of legislation has been adopted in 
order  to  protect  consumers.  They  provide,  in  general, 
consumers with a legal guarantee of high level quality products 
and  services.  They  also  contain  provisions  dedicated  to  the 
redress of damages resulting from sub-standard products and 
services.
Even if these texts are not directly dedicated to products and to 
services  that  are  supplied  by  healthgrid  systems  or  that 
compose them, they can be easily applied there. In this section 
we  will  therefore  first  consider  the  European  legislation 
applicable  to  the  information  contained  in  the  healthgrid 
systems or to the products and the services supplied by these 
systems. We will then look at the legal texts to determine the 
responsibilities  of  the  different  actors  of  healthgrids,  in 
particular as regards the elements that compose these systems. 
Finally, we shall outline some general eHealth situations, such 
as  pharmaceutical  products  sold  via  Internet  and  contracts 
concluded electrically, in which the particular responsibility of 
certain actors of the system is determined.
2.3.2.Who bears responsibility for the security of data in a 
healthgrid? 
As stated in the first part of this document, processing of personal data requires 





In   terms of   confidentiality,   any  person  acting  under  the   authority   of   the  data 
controller or of the data processor, including the data processor himself, who has 
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must   implement   appropriate   technical   and   organisational   measures   to   protect 
personal data. There are thus three important actors: the data controller, the data 
processor and the network controller, who have to protect personal data against 
accidental   or   unlawful   destruction   or   accidental   loss,   alteration,   unauthorised 
disclosure or access, etc. 
If  a  healthgrid  is  not  maintained  securely  and  the  data  in  it  can 
become corrupted and in turn give rise to incorrect and/or misleading 
data  outputs  which  could  result  in  harm  to  a  patient,  the  data 
controller would then be liable in case of damage caused to a patient 
and he would be responsible to compensate for the damage. Article 23 
of the Data Protection Directive provides that  “Member States shall  
provide that any person who has suffered damage as a result of an  
unlawful  processing  operation  or  any  act  incompatible  with  the 
national provisions adopted pursuant to this Directive is entitled to 
receive compensation from the controller for the damage suffered”.
However, the data controller would have a defence if  he could prove 
that he is not responsible for the event giving rise to the damage. He 
could, for example, prove that a default of maintenance of the system 
by the network controller gave rise to the patient’s damage.
2.3.3.Do  website  hosts  have  a  legal  liability  for  what 
happens on the site?




25  Directive 95/46/EC, art. 16.
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type of scenario a website would automatically be populated with data to advise 
travellers on vaccination needs. The question might therefore arise as to who would 
be   liable  if   the  website  showed an   incorrect  body of  data   and a   citizen were 
harmed?
The   “eCommerce”   Directive   2000/31   on   certain   legal   aspects   of   information 






Internet   intermediaries   providing   information   society   services   called   ‘Mere 
Conduit’, ‘Caching’ and ‘Hosting’ under specific circumstances.
Mere Conduit: “Mere Conduit” consists in the transmission in 
a  communication  network  of  information  provided  by  a 
recipient  of  the  service  or  the  provision  of  access  to  a 
communication network. A mere conduit service provider is not 
liable for the information transmitted as long as the provider 
does  not  initiate  the transmission  nor  select,  nor  modify  the 
information contained in the transmission.
Caching: A  caching  service  provider  is  not  liable  for  the 
automatic, intermediate and temporary storage of the ‘cached’ 
information,  performed for  the sole  purpose  of  making  more 
efficient  the  information's  onward  transmission  to  other 
recipients of the service upon their request. A caching service 
provider  must  not  modify  the  information  stored.  He  must 
comply with conditions on access to the information, with rules 
regarding  the  updating  of  the  information.  He  must  not 
interfere with the lawful use of technology to obtain data on the 
use of the information; and must act quickly to remove or to 
disable access to the information stored upon obtaining actual 
knowledge of the fact that the information at the initial source 
of  the  transmission  has  been  removed  from the  network,  or 
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access  to  it  has  been  disabled,  or  that  a  court  or  an 
administrative  authority  has  ordered  such  removal  or 
disablement.
Hosting:  When  providing  a  “Hosting”  service,  the  service 
provider is not liable for the information stored at the request of 
a  recipient  of  the  service.  The  hosting  provider  must  not 
however have actual knowledge of illegal activity or information 
and, as regards claims for damages, is not aware of facts or 
circumstances from which the illegal activity or information is 
apparent.  If  he  becomes  aware  of  such activity  he  must  act 
quickly to disable access to the information.
2.3.4.Who is responsible if a faulty product is delivered 
through a healthgrid?
Although a healthgrid itself will not deliver a product, it might be the direct link 
to   the   delivery   of   a   product   in   that   a   product   might   be   delivered   through 




eStockmanagement   and   eProcurement,   for   outpatients   and   discharged   patients. 
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compensation. Any liability issue will thus normally depend on the general rules of 
law applicable in the different EU Member States. 
2.3.5.What  is  the  EU  doing  to  protect  citizens  in  this 
context of vague legal duties and responsibilities?
The European legislation around product and services liability can be distinguished 
into two broad types: 1. those concerned with the prevention for harm and 2. those 




2.3.6.Why is Directive 2001/95 on general product safety 
relevant to healthgrids? 
The  Directive  on  General  Product  Safety  imposes  a  general 
safety  requirement  to  products  placed  on  the  market  and 
intended  for  consumers  or  likely  to  be  used  by  them.  The 
Directive  is  designed  to  ensure  that  producers  put  on  the 
market only products that are not likely to cause any threat (or 
only  a  reduced  threat  in  accordance  with  the  nature  of  the 
product’s  use)  and  that  allow  the  effective  protection  of 
consumers’  health  and safety.  In  addition,  they must  provide 
consumers with relevant information to enable them to assess 
the risks inherent to the product, particularly when these risks 
are  not  obvious.  They  must also  take  appropriate  actions  to 
avoid  these  risks  (withdrawal  of  unsafe  products  from  the 
market,  warning of  the consumers,  recall  of  unsafe products 
already supplied, etc.). 
In order to understand the impact this legislation will have on 
healthgrids,  we  must  first  establish  what  sort  of  products  it 
applies to – and define ‘product’. In the framework of Directive 
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2001/95,  the  term  ‘product’  means  any  product  which  is 
intended for consumers or likely, under reasonably foreseeable 
conditions, to be used by consumers even if  not intended for 
them,  and  which  is  supplied  or  made  available,  whether  for 
consideration or not, in the course of a commercial activity, and 
whether  new,  used  or  reconditioned.  Therefore,  products 
initially  reserved  for  professional  use  that  are  subsequently 
made available to consumers are also covered by the Directive’s 
definition of the term product. 
The Directive applies only to goods and products on the market for 
consumers to acquire,  whether for  free or for  consideration.  Since 
most healthgrids applications are not yet designed or foreseen for the 
general  market,  the  Directive has  only  limited application for  now. 
However,  once that  changes,  the  Directive will  become relevant  to 
suppliers of Grid component software – some of which may have a 
health application. We can already see the use of grid computing in 
consumer  areas  such  as  digital  content  sharing  and  application 
service provisioning, it is surely only a matter of time before some of 
those applications are also in the health arena.
2.3.7.How does the General Product Safety Directive work 
in practice?
Member  States  have  established  or  designated  national 
authorities to monitor product safety and to take appropriate 
measures as regards risky products.  Every national  authority 
must ensure that producers and distributors comply with their 
duties and are entitled to ensure product safety by organising 
checks  on  safety  properties,  by  imposing  producers  to  warn 
adequately  on  the  possible  risks,  by  prohibiting  dangerous 
products to be marketed, by alerting consumers on the risks of 
a  product  already  marketed  and  by  organising  recalls  and 
destruction of products when necessary. 
Any producer or distributor who discovers that a product is dangerous 
must notify the competent national authority and collaborate with it to 
ensure  that  all  relevant  consumers  are  made  aware  of  the  risks. 
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Directive 2001/95 also aims to create an efficient information system 
in  order  to  help  EU  Member  States,  national  authorities  and 
consumers to react quickly in order to avoid or to reduce any harm 
caused to persons’ health and safety.
2.3.8.And what if something goes wrong anyway? 
When a defective product causes damages, rules contained in 
Directive  83/374/EEC on Liability  for  Defective  Products  will 
apply.26 This Directive aims at ensuring a high level of consumer 
protection against damage to health or property by a defective 
product. It also aims to reduce the disparities between national 
liability  laws  that  distort  competition  and  restrict  the  free 
movement  of  goods.  Finally,  it  implements  a  system  that 
extends the producer’s liability (called the ‘strict  liability’)  in 
order to protect consumers. 
When the producer, importer or supplier, is considered as liable, 
he must pay compensation for the damage caused to the person 
or to his properties, but only for that resulting from a defect. 
Though, in order to strike a reasonable balance between the 
interest of the consumer and the need to encourage innovation 
and  technological  development,  the  Directive  contains  some 
rules protecting the producer.  Also,  the injured person has a 
limited period of three years to seek compensation. This period 
starts from the day on which the claimant became aware, or 
should  reasonably  have  become  aware  of  the  damage,  the 
defect and the identity of the producer. After that, no further 
compensation  will  be  possible.  In  any  case  the  producer’s 
liability  is  limited to a  period of  ten years  from the date  on 
which the producer puts the product into circulation. This time 
limit is intended to preserve a balance between consumers’ and 
producers’ interests. 
26  Council  Directive  85/374  of  25  July  1985  on  the  approximation  of  the  laws,  regulations  and 
administrative provisions of the Member States concerning liability for defective products, O.J. L210, 7 
August 1985, p. 29-33.
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Directive  85/374  Liability  for  Defective  Products  establishes  the 
principle  of  objective  liability  (or  liability  without  fault)  of  the 
producer,  importer  and  in  some  circumstances  the  supplier  of  a 
defective product. The producer, importer or supplier, will be liable 
and  must  pay  compensation  for  damages  caused  to  persons  or 
properties  but  only  for  that  resulting  from a  defect.  The  claimant 
person  does  not  have  to  prove  that  the  producer  was  at  fault  or 
negligent; he simply needs to prove the damage, a defect and a direct 
causal relationship between defect and damage.
2.3.9.Does  any  other  law  protect  a  consumer  in  a 
healthgrid? 
One of the important goals of the healthgrid systems used in the 
healthcare  sector  will  be  to  deliver  medicinal  products  or 
medical  devices  to  patients.  The  patients  can  thus  acquire 
products  necessary  for  the  preservation  of  their  health  by 
means of the system.  Therefore in the eHealth arena, when the 
product delivered does not conform to what was foreseen in the 
contract,  citizens  can  have  recourse  to  the  relevant  national 
legislation  based  on  the  Directive  1999/44/EC  on  Sale  of 
Consumer Goods. 27 
According to the Directive on Sale of Consumer Goods when consumer goods are sold 







27  Directive 1999/44 of the European Parliament and of the Council of 25 May 1999 on certain aspects of 
the sale of consumer goods and associated guarantee, O.J. L171, 7 July 1999, p. 12-16.
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In  the  framework  of  Directive  1999/44,  the  definition  of  the 
consumer  is the same as the one of Directive 1997/7 on the 
protection of consumers in respect of distance contracts.28 The 
consumer is thus described as any natural person who, in the 
contracts covered by the Directive, is acting for purposes that 
are not related to his trade, business or profession. Consumer 
goods covered by the Directive are any tangible movable item 
(except goods sold by authority of law, water and gas where 
they are not put up for sale in a limited volume or set quantity, 
and electricity). 
The seller is any natural or legal person who, under a contract, 
sells  consumer goods in the course of  his trade,  business or 
profession, when the producer is defined as the manufacturer 
of consumer goods, the importer of consumer goods into the 
territory of the Community or any person purporting to be a 
producer by placing his name, trademark or other distinctive 
sign on the consumer goods.
2.3.10.So what does the Directive on Sale of  Consumer 
Goods mean to ordinary people?
The  seller  has  to  deliver  to  consumers  goods  that  are  in 
conformity with the contract of sale.
Consumer  goods  are  presumed to  be  in  conformity  with  the 
contract if they: 
(a)comply with the description given by the seller and 
possess the qualities of the goods which the seller 
has held out to the consumer as a sample or model; 
(b)are fit for the purposes for which goods of the same 
type are normally used;
(c) are  fit  for  any  particular  purpose  for  which  the 
consumer requires them and which he made known 
28  Directive 1997/7 on the protection of consumers in respect of distance contracts,  O.J. L144,  4 June 
1997, p. 19-27.
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to the seller at the time of conclusion of the contract 
and which the seller has accepted; 
(d)show the quality and performance which are normal 
in goods of the same type and which the consumer 
can  reasonably  expect,  given  the  nature  of  the 
goods  and  taking  into  account  any  public 
statements  on  the  specific  characteristics  of  the 
goods made about them by the seller, the producer 
or his representative, particularly in advertising or 
on labelling. 
The seller is not liable if, at the time the contract was 
concluded, the consumer was aware, or could not reasonably be 
unaware of, the lack of conformity, or if the lack of conformity 
has its origin in materials supplied by the consumer. 
2.3.11.But healthgrid systems are not only about data and 
products!
Services might also be delivered through healthgrids, such as virtual courses in real 
time   for   undergraduate  graduate   students,   young   professionals   in   the   case   of 
medical  eLearning  or   for  matters  such   as   second opinions,   demonstrations,  or 
medical assistance of tourists or expatriates.
Equally   simulations   and modelling   for   therapy  planning  and  computer­assisted 
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are diverse. They might be passive services, such as supplies of general medical 
information through networks or Internet workstations for end­users. They might 
also   be   active   services   like   medical   advice   or   specific   decision   support   to 
clinicians, or might involve the collection of biomedical data for remote monitoring 
by clinicians. 








2.3.12. And what if a healthgrid forms part of a medical 
device?
When a product considered as a medical device is placed on the 
market, specific additional rules regarding the safety of those 
particular  products  apply.  Directive  93/42/EC  concerning 
medical devices29 aims notably to safeguard patients’ and users’ 
health  and  safety  by  harmonising  the  conditions  for  placing 
medical devices on the market and putting them into service. 
Among other conditions, medical devices must be designed and 
29  Council Directive 93/42 of 14 June 1993 concerning medical devices, O.J. L169, 12 July 1993, p. 1-43.
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manufactured in such a way that their use does not compromise 
the safety and health of patients, users and other persons when 
properly  installed,  maintained  and  used  in  accordance  with 
their intended purpose.
Moreover EU Member States are involved in the protection of 
patients. Indeed, when one of them notes that a medical device 
conforming  to  the  Directive’s  prescriptions  compromises  the 
health  and/or  safety  of  patients,  users  or,  where  applicable, 
other persons, it shall take all appropriate interim measures to 
withdraw it from the market, prohibit or restrict it being placed 
on the market or put into service. 
2.3.13.So what is a Medical Device?
According to the Directive’s text, a ‘medical device’ is: 
“ […] any instrument, apparatus, appliance, material or 
other  article,  whether  used  alone  or  in  combination, 
including  the  software  necessary  for  its  proper 
application intended by the manufacturer to be used for 
human beings for the purpose of: 
- diagnosis,  prevention,  monitoring,  treatment  or 
alleviation of disease, 
- diagnosis,  monitoring,  treatment,  alleviation  of  or 
compensation for an injury or handicap, 
- investigation,  replacement  or  modification  of  the 
anatomy or of a physiological process, 
- control of conception,
and which does not achieve its principal intended action 
in  or  on  the  human  body  by  pharmacological, 
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immunological  or metabolic means,  but  which may be 
assisted in its function by such means”.
The accessories that are not medical devices as such, but that 
are specifically intended to be used together with a device to 
enable it to be used as wanted by the manufacturer, shall be 
treated as medical devices. 
For vendors and users of healthgrid systems it is important to note 
that electronic equipment and software must be regarded as within 
the  definition  of  medical  device,  when  they  are  manufactured  or 
promoted for medical purpose.
According to  the  Guidelines  Relating to  the Medical  Devices 
Directive30 available on the website of DG Enterprise,31 software 
related  to  the  functioning  of  medical  devices  are  medical 
devices on their own if placed on the market separately from 
the related devices.  When software helps to emit a diagnosis 
(like  image  enhancing  software  created  for  diagnostic 
purposes), or is a therapeutic tool, it has to be considered as a 
medical device. This is not the case for software used for the 
administration of general patient data. 
The manufacturer’s obligations set out in the Directive,  must 
also be fulfilled by the natural or legal person who assembles, 
packages, processes, fully refurbishes and/or labels one or more 
ready-made  products  and/or  assigns  to  them  their  intended 
purpose as a device. This subparagraph does not apply to the 
person who, while not being a manufacturer within the meaning 
30 These guidelines aim at promoting a common approach by manufacturers and Notified Bodies involved 
in the conformity assessment procedures according to the relevant annexes of the Directive and by the 
Competent  Authorities  charged  with  safeguarding  Public  Health.  Nevertheless,  they  are  not  legally 
binding. However, due to the participation of the aforementioned interested parties and of experts from 
Competent  Authorities,  it  is  anticipated  that  they  will  be  followed  within  the  Member  States  and, 
therefore, ensure uniform application of relevant Directive provisions.
31 For details and references see http://ec.europa.eu/enterprise/medical_devices/meddev/index.htm.
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of the first subparagraph, assembles or adapts devices already 
on  the  market  to  their  intended  purpose  for  an  individual 
patient.
In the Directive’s context,  manufacturers  are obliged to place 
on the market or to put into service only medical devices that 
do not compromise the safety and health of patients, users and, 
where  applicable,  other  persons,  when  properly  installed, 
maintained  and  used  in  accordance  with  their  intended 
purpose.  The  manufacturer  must  design  and  manufacture 
medical  devices in  such  a  way  that  some  ‘essential 
requirements’  are  met,  such  as  to  take  into  account  the 
generally  acknowledged  state  of  the  art  and  to  eliminate  or 
reduce risks as much as possible (like the risks linked to the 
toxicity  of  certain  materials  and  their  incompatibility  with 
biological  tissues and cells,  or  the risks of  contamination for 
persons involved in the transport, storage and use of medical 
devices).
Devices  that  are  in  accordance  with  the  national  provisions 
transposing the existing  European harmonised standards  will 
be  presumed  by  EU  Member  States  as  compliant  with  the 
essential  requirements  laid  down  by  the  Directive.  Devices 
other than those which are custom-made or intended for clinical 
investigation must bear a CE conformity mark when placed on 
the market.
2.3.14.What  about  the  electrical  equipment  that  forms 
part of the components of a healthgrid?
When the products manufactured are electrical or constitute electronic equipment, 
like IT or telecommunications equipments, they shall respect the provisions of the 
RHoS  Directive,   which   relates  to   restrictions   of   the   use   of   certain   hazardous 
substances   in   electrical   and   electronic   equipment.   This   Directive   imposes 
manufacturers   to   avoid   using  lead,   mercury,   cadmium,   hexavalent   chromium, 
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2.3.15.What  about  the  liability  in  more  general  issues 
such as Internet based health information provision 
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So far we have  looked at  the EU level  Directives and Guidelines  that regulate 
liability for goods and services provision, and we have noted that most of  it  is 
applicable to healthgrids by analogy only. Thus, were a healthgrid forms part of a 
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In the context of contracting it  should be noted that  electronic signatures  are, 
according  to  EU  legislation,   to be  treated as equal  to hand written signatures. 
Different   kinds  of   electronic   signatures   exist,   from  the  very   simple  ones  (the 
insertion of a scanned hand­written signature within an electronic document), to 




32  Directive 97/7 on the protection of consumers in respect of distance contracts, O.J. L144, 4 June 1997, 
p. 19-27.
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for   a  medical order   in   a   legal  proceeding  the  judge cannot  a priori  refuse  to 
consider this type of signature but must analyse, with possibly the help of experts, 




We have seen that determining the responsibilities of each actor 
within the framework of healthgrid systems is not easy. While 
the rules on Data Protection are reasonably well adapted to the 
eHealth  domain  generally,  the  same  cannot  be  said  for  the 
liability rules which will  apply to a wide range of actors and 
which will  need to be determined legally in the event that a 
patient suffers harm as a result of a decision taken on the basis 
of information shared through a healthgrid.
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Accordingly it is important the existing European framework of 
general  product  safety  is  re-examined  to  consider  its 
applicability to distributed networks such as healthgrids. 
Furthermore the law on medical devices is very unclear with 
respect to healthgrids. While it may be argued that a healthgrid 
could  fall  within  the  ambit  of  the  current  Medical  Devices 
Directive in that it is a software tool that impacts on a medical 
act,  the  whole  construction  of  the  Directive  is  based  upon 
physical goods (which might have a software component) that 
are placed on the market for purchase or lease, it is ill adapted 
to deal  with the shared domain of grid-based services where 
software sold and owned by a wide range of participants.
It  would seem therefore that at present the only real way to 
have clarity  over  liability  for  the possible  negative  effects  of 
healthgrids is through tightly constructed contracts in private 
law.  If  however  the  use  of  healthgrids  across  EU  and 
international  borders in  shared public/private initiatives  is  to 
become  a  reality  then  steps  should  be  taken  to  develop 
guidelines  and  possibly  legislation  to  harmonise  the  legal 
expectation of all actors in a healthgrid.
2.4. INTELLECTUAL PROPERTY RIGHTS
2.4.1.Introduction
The  healthgrid  vision  relies  on  the  setting  up  of  grid 
infrastructures  for  medical  research,  healthcare  and  life 
sciences.  This  implies  the  availability  of  data  organised  in 
databases.  This  also  implies  the  availability  of  grid  services, 
most notably for data and knowledge management.33
A fully functioning healthgrid will be composed of a data grid, 
i.e.  a  distributed  and  optimised  storage  of  large  amounts  of 
33  These services  must  be  deployed on  infrastructures  involving  healthcare  centres  (e.g.  hospitals), 
medical  research  laboratories  and  public  health  administrations.  For  details  on  this  point  see, 
SOLOMONIDES,  T.,  “Structuring  and  supporting  healthgrids  Activities  and  Research  in  Europe 
(SHARE): towards a European healthgrid, step one”, e-Science 2006, Amsterdam, 4-7 December 2006.
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accessible information and of a computing grid which implies 
the utilisation of numerous computers, computer programmes 
and  other  electrical  components.  The  final  part  of  a  full 
healthgrid would be a  knowledge grid or in other words, the 
intelligent  use  of  a  data  grid  for  knowledge  creation.  This 
knowledge  grid  has  not  yet  been  deployed.  As  we  say 
repeatedly  in  this  document,  a  healthgrid  is  thus  mainly 
composed  of  computers  and  computer  programs  and 
encompasses databases.
As  the  implementation  of  healthgrids  on  the  territory  of  the 
European  Union  grows,  so  will  the  protection  of  databases 
assume an increased importance, given that most grid services 
will  be  provided  via  electronic  databases  accessible  online, 
offline  or  accessible  via  European-wide  networks.  Databases 
should therefore be accorded an appropriate level of protection 
so as to create an attractive environment for investments while 
safeguarding users’ interests.
As  researchers  Laura  Vilches  Armesto  and  Philippe  Laurent 
noted,  medical  data  is  usually  addressed  by  lawyers  from a 
privacy point of view. As they go on to say,
“However  intellectual  property  is  increasingly  put 
forward  when  discussing  the  control,  the  use  or  the 
transmission of medical data. Even if medical data relates  
to patients and is moreover protected by very strict data 
protection  and  secrecy  rules,  this  information  is 
nonetheless “created”, sorted, structured, explained and,  
more  generally,  processed  by  professional  practitioners 
and medical administrations. Given this processing of the 
data and drafting of files and reports concerning health 
condition of patients, one could indeed assume that these 
intellectual  investments  should  be  worth  some  legal 
protection”.34
34  Laura  VILCHES  ARMESTO  and  Philippe  LAURENT,  « Intellectual  property  on  medical  data  - 
chimaeras and actuality »,  Acts of the 16th World Congress on Medical Law,  Toulouse, 7-11 August 
2006, p. 747-754.
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This  is  not  the  case  only  for  medical  data:  adequate  legal 
protection  is  also  required  for  molecular  data,  cellular  data, 
tissue data and even population data.
We will therefore look in some detail at the EU level legislation 
that seeks to protect intellectual property in databases as well 
as certain aspects of the law of copyright.
2.4.2.What does Directive 96/9/EC on the legal protection 
of databases mean for healthgrids?
The Directive on the legal protection of databases, which was 
adopted in February 1996, can apply to databases constituted of 
medical, genetic or even general data, as regards its definition 
of a database. The Directive creates a legal framework of rules 
for  the  protection  of  a  wide  variety  of  databases  in  the 
information age by giving a high level of copyright protection to 
“original”  databases35 and  a  new  form  of  “sui  generis” 
protection to those databases which were not “original” in the 
sense of the author’s own intellectual creation (those databases 
are  also  called  “non-original”  databases).  In  other  words  the 
Directive  introduced a  new specific  sui  generis right  for  the 
creators of databases, whether or not these have an intrinsically 
innovative nature.
The  Directive  defines  a  database  as  “a  collection  of  independent 
works, data or other materials arranged in a systematic or methodical 
way  and  individually  accessible  by  electronic  or  other 
means”(art1(2)).It thus applies to databases in any form, but does not 
apply to the software used in the making or operation of the database 
or to the works and materials contained therein. Nor does it affect the 
legal provisions covering patents, marks, designs and models or unfair 
competition that can apply to the database or to its contents. Given 
this wide definition, the Directive can apply to much of the contents of 
a healthgrid.
35  See infra for a definition of this concept.
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2.4.3.What sort of database can be copyrighted?
First,  it  must  be  remembered  that  the  granting  of 
copyright does not require any specific legal procedure. 
Any  literary  or  artistic  works,  which  includes  amongst 
others, any production in the scientific domain36, so long 
as the works are expressed in a certain form and are original, 
can  be  copyright  material.  Copyright  will  therefore  usually 
apply to the structure of databases, but rarely to the content 
(unless that is totally original too). To gain copyright, a database 
must  have  originality  in  the  selection or  arrangement  of  the 
contents  and  may  be  regarded  as an  intellectual  creation 
particular  to  its  author.  Each individual  item included in  the 
database  may  or  may  not  be  in  copyright,  depending  on  its 
originality.
A database of electronic health records could then be capable of 
being copyrighted,  given that the healthcare practitioner has 
completed the records in an elaborate and original way. This 
could  also  be  the  case  for  genetic37 or  tissue  databases. 
36  Definition proposed in « Intellectual property on medical data - chimaeras and actuality », opcit,  p. 
747.
37  For a detailed analysis of copyright protection for genetic databases in the United States see, Ray K. 
HARRIS and Susan Stone ROSENFIELD, “Copyright Protection for Genetic Databases”, 45 Jurimetrics, 
2005, p. 225-250.
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Copyright protection could apply to the database comprised of 
tissue  samples  once  the  tissue  data  were  coordinated  and 
arranged in an original structure that could for instance help 
researchers.
2.4.4.What  rights  does  Copyright  give  the  creator  of  a 
database?
The creator or the author of the database enjoys a group of 
exclusive rights to carry out or to authorise:
(a)temporary or permanent reproduction by any means and 
in any form, in whole or in part;
(b)translation, adaptation, arrangement and any other 
alteration;
(c) any form of distribution to the public of the database or of 
copies thereof. The first sale in the Community of a copy 
of the database by the right holder or with his consent 
shall exhaust the right to control resale of that copy 
within the Community;
(d)any communication, display or performance to the public;
(e)any reproduction, distribution, communication, display or 
performance to the public of the results of the acts 
referred to in (b).38
However, a legitimate user of a database may perform all the 
acts referred to in article 5 of the Directive that are necessary 
for using the database. 
However,  the  protection  granted  to  databases  by  Directive 
96/9/EC might seem insignificant compared to the efforts and 
the  energy  demonstrated  by  data  grid  creators  in  order  to 
retrieve  in  each  case,  molecular,  cellular,  tissue  or  personal 
data. Only the structure of these databases is protected, while 
value for sure still resides in the samples of the databases for 
development  of  enhancements,  competing  technologies  or 
follow-on products.
38  Directive 96/9/EC on the legal protection of databases, art. 5.
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2.4.5.But what about protecting the data content of the 
healthgrid?
Directive 96/9/EC introduced another protection for databases 
besides copyright. It created a new exclusive  sui generis right 
for  database  producers.  Sui  generis rights  protect  the 
substantial  investment  of  the  database  producer  from  a 
quantitative  and  qualitative  perspective,  in  the  obtaining, 
verification or presentation of the contents of the database.39 
There  is  thus  a  new  EU  level  protection  granted  for  the 
investment made (financial and in terms of human resources, 
effort and energy) in the obtaining, verification or presentation 
of the contents of a database. 
So, in terms of protection granted, the difference between the 
structure,  the  content  and  the  investment  made  for  the 
development  of  a  database  is  very  important.  Traditional 
copyright  protects  the  structure  of  databases,  while  sui 
39  Directive 96/9/EC on the legal protection of databases, art. 7(1). See also recitals 40 to 42 of the 
Directive.
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generis rights  protect  the  investment  made  for  the 
development of databases.
In the framework of sui generis protection, the producer or the 
maker of a database (i.e. the person who made the investment), 
whether  a  natural  or  a  legal  person,  can  prohibit  the 
unauthorised retrieval and/or re-use of its contents.40 Protection 
against  unauthorised  retrieval  or  re-use  is  accorded  to 
databases  whose  maker  is  a  national,  a  company  or  an 
undertaking  resident  in  or  having  his/its  registered  office, 
central  administration  or  principal  place  of  business  in  the 
Community.
2.4.6.Does  that  mean no one can use the content  of  a 
healthgrid database without consent?
No, the Directive states that  “non-substantial  extractions and 
reuses may be undertaken by third parties, without the right 
owner’s authorisation, as long as these acts are not made in a 
repeated and systematic way that would imply a conflict with 
the  normal  exploitation  of  the  database  or  produce  an 
unreasonable  prejudice  to  the  legitimate  interests  of  the 
database’s maker”.41
The  fact  that  non-substantial  parts  of  a  database  may  be 
extracted  and  re-used  in  another  database  might  cause  a 
prejudice  to  other  interests  than  the  ones  of  the  database 
maker.  For  instance,  the  extraction  of  information  from  a 
database containing medical records might cause a prejudice to 
patients’ rights. There can thus be a contradiction between this 
right  to  re-use  non-substantial  parts  of  a  database  to  create 
another database for example and the legislation applicable to 
40  Directive  96/9/EC  on  the  legal  protection  of  databases,  art.  7(1).  The  terms  extraction  and  re-
utilisation are defined in article 7(2) of the Directive. In this framework, extraction shall be seen as the 
permanent or temporary transfer of all or of a substantial part of the contents of a database to another 
medium by any means or in any other form. On the other hand, re-utilisation shall mean any form of 
making available to the public all or a substantial part of the contents of a database by the distribution 
of copies, by renting, by on-line or other forms of transmission. The first sale of a copy of a database 
within the Community by the right holder or with his consent shall exhaust the right to control resale 
of that copy within the Community.
41  Directive 96/9 on the legal protection of databases, art. 7(5), a contrario. 
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the protection of the data which requires for any re-use of data 
relative to a patient, the agreement of the patient. 
Furthermore, the right to prevent even substantial extraction 
and re-use of the contents of a database extends for a period of 
15 years with effect from the date on which the database was 
terminated.42
A further point to note is that during the 15 year period,  sui 
generis rights  are  pecuniary  rights  and  as  such  can  be 
transferred,  assigned  or  granted  under  contractual  licence43. 
Again, this is of importance when the data are personal medical 
data.
The  combination  of  these  two  principles,  i.e.  the  economic 
nature of the sui generis rights and their term of protection for 
a  period  of  15  years,  may  constitute  an  impediment  for  the 
deployment of healthgrids. Database makers could for example 
charge  third  parties  wanting  to  develop  data  grids  before 
granting  them  their  sui  generis rights  under  contractual 
42  Directive 96/9 on the legal protection of databases, art. 10(1). In the case of a database which is made 
available to the public in whatever manner before expiry of the period provided for in paragraph 1 of 
article 10, the term of protection by that right shall expire fifteen years from the first January of the 
year  following  the  date  when  the  database  was  first  made  available  to  the  public.  Finally  any 
substantial change, evaluated qualitatively or quantitatively, to the contents of a database, including 
any  substantial  change  resulting  from  the  accumulation  of  successive  additions,  deletions  or 
alterations, which would result in the database being considered to be a substantial new investment, 
evaluated qualitatively or quantitatively, shall qualify the database resulting from that investment for 
its own term of protection (art. 10(3)).
43  Directive 96/9 on the legal protection of databases, art. 7(3).
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licence. There might thus be an impediment in terms of costs to 
the implementation of healthgrids.  On the other hand, in the 
pharmaceutical  sector,  researchers  might  claim  sui  generis 
rights on certain databases. Such claims could delay the release 
of  other  products  which  could  have  been  discovered  on  the 
basis  of  the  information  contained  in  the  first  database 
compiled in another way. 
Given  these  constraints  it  should  not  be  surprising  that 
businesses  in  the  Member  States  have  not  welcomed  the 
Directive with open arms. Indeed an evaluation conducted on 
the basis of a 2005 online survey addressed to the European 
database industry and of the Gale Directory of Databases (the 
“GDD”) showed that the sui generis right seem to have caused 
considerable legal uncertainty. DG Internal Market and Services 
invited  stakeholders  to  comment  on  four  options:  repeal  the 
whole directive (option 1); withdraw the sui generis right while 
leaving protection for creative databases unchanged (option 2); 
amend the sui generis provisions in order to clarify their scope 
(option  3);  maintain  the  status  quo  (option  4).  Although  a 
significant number of responses were received the Commission 
found  the  results  inconclusive  and  have  invited  further 
comments from stakeholders on economic repercussions of this 
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type of protection. At the time we publish this document (winter 
2006-spring 2007), that consultation is still open.
2.4.7.What  does  the  Copyright  legislation  mean  for 
patients’ data?
A database author has the right to control the reproduction and 
the communication of his work to the public. However, it is not 
certain how that right balances against the rights of patients 
whose data is  held within the database.   Some authors have 
argued that when a database is constituted of electronic health 
records, cellular or tissues, the work is “[…] created with data 
relating  to  patient(s),  (their)  bodies,  (their)  health  and  the 
treatment they undergo. These data (are) subject to very strict 
sensitive data protection and privacy rules”.44 Thus the patient’s 
rights and the protection of sensitive data are superior to the 
copyright which would have a direct impact on the exercise of 
authors’  exclusive  rights.  For  instance,  an  author  could  not 
prohibit to the patient the access to and the use of a copy of his 
medical record. The author or copyright owner could thus no 
longer exercise their exclusive rights alone. This  could impede 
the  development  of  databases  and  as  a  consequence  the 
development of healthgrids. 
One of the possible solutions would be to introduce a distinction 
between  various  types  of  data,  as  the  medical  data  and  the 
health data or sanitary data.  In the case of electronic health 
records, it would be advisable among others to determine the 
status of the personal notes of the doctor. Indeed, most of the 
blockings seem to come from the absence of clear and precise 
definition of the notion of medical datum.45
2.4.8.What  about  Intellectual  Property  Rights  and 
Biobanks?
44  « Intellectual property on medical data - chimaeras and actuality », opcit, p. 748.
45  Philippe VANLANGENDONCK,  « Le  dossier  médical  électronique :  problèmes de vie  privée et  de 
responsabilité », sur http://www.droit-technologie.org, p. 1-10. For developments on this topic see the 
Roadmap document. 
FP6­2005­IST­027694 PUBLIC  61 / 96
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, A. 
Dobrev, J. Herveg, V. 
Stroetmann, K. 
Stroetmann, C. Van 
Doosselaere, P. Wilson 
As  already  mentioned  in  this  document,  a  database  is  a 
collection of independent elements, including artistic, literary, 
musical  works,  texts,  data  or  other  materials  arranged  in  a 
systematic  way  and  individually  accessible  by  electronic  or 
other means.46 
It  contains  a  wide  range of  items that  may  be  protected by 
copyright  –  as  explained  above  –  and  by  other  intellectual 
property rights such as patents.
This  is  especially  the  case  for  biobanks,  i.e.  for  databases 
containing biological materials. Biobanks are mainly used in the 
drug discovery sector, by pharmaceutical companies, research 
laboratories,  universities  or  hospitals,  in  order  to  ‘test  drive’ 
medicinal products to be put on the market. In the field of drug 
discovery, various actors with different interests collaborate to 
the  development  of  future  medicinal  products.  The  different 
intellectual  property rights applicable  to biobanks render the 
situation even more complicated for those actors. 
Biobanks are to be considered as databases. The fact that they 
contain biological material does not lead to their exclusion from 
46  Recital 17 and article 1, paragraph 2 of Directive 96/9/EC on the legal protection of databases.
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the database regime. Biobanks are thus to be seen as composed 
of structures and contents.
As already explained in this document, copyright protects the 
structure, as long as it is original. The way different biological 
materials are sorted,  classified, linked together and rendered 
accessible through menus or entries, may thus be copyrighted.
But in this context,  contracts  will play a key role in order to 
determine  who  will  be  the  copyright  owner  of  a  particular 
database.  Indeed,  depending  on  the  terms  of  the  contracts 
pertaining to the creation of the structure of the biobank, and 
their role in that creation either the practitioner, the hospital or 
any other contractor such as a pharmaceutical company or any 
combination  of  them could  be  the  copyright  owner.  In  some 
cases, this could help a research laboratory or a pharmaceutical 
company to prevent that the medicine it discovered be copied 
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by a  competitor.  In  that  context,  however,  it  is  important  to 
underline  that  some  third  parties  such  as  universities  or 
academic  research  laboratories  might  benefit  from  certain 
exceptions to the ban to copy or to communicate the database’s 
structure to the public, in specific circumstances such as the 
use of the database for teaching or scientific research purposes.
Biobanks  may  also  be  protected  by  sui  generis rights.  The 
owner of those rights will then be the hospital or the research 
laboratory that has made the investment in order to constitute 
the database. The sui generis rights owner will then be allowed 
to  prohibit  the  substantial  extractions  and  re-use  of  the 
database by any third party. In the drug discovery sector, this 
could also be of importance for pharmaceutical companies or 
research laboratories  developing medicinal  products.  The  sui 
generis rights  will  help  them  protect  their  discoveries  by 
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preventing any competitor to copy their biobanks in order to 
develop similar products.
However it is important to note, as researchers  Laura Vilches 
Armesto and Philippe Laurent do47, that the  sui generis rights 
protection  is  weaker  than  copyright  because  only  biobanks 
demanding a substantial investment for their constitution may 
be protected. 
Furthermore,  in  application  of  Directive  1996/9/EC,  “non-
substantial  extractions  and  re-uses  of  a  database  may  be 
undertaken  by  third  parties,  without  the  right  owner’s 
authorisation, as long as these acts are not made in a repeated 
and systematic way that would imply a conflict with the normal 
exploitation  of  the  database  or  produce  an  unreasonable 
prejudice to the legitimate interests of the database’s maker”.48
47  « Intellectual property on medical data - chimaeras and actuality », opcit, p. 752.
48  Directive 96/9 on the legal protection of databases, art. 7(5), a contrario. 
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Finally, according to the spin-off  theory49 a biobank that would 
result from activities whose main purposes are not the creation 
of a database for drug discovery for example, could not benefit 
from the sui generis rights protection.
Last but not least, the content of biobanks, i.e. the biological 
materials contained in biobanks could also be patented. Indeed, 
the research carried  out  and the developments  made on the 
basis  of  biobanks’  contents  could  result  in  inventions,  more 
specifically in biotechnological inventions. 
At European level, these inventions are protected by Directive 
98/44/EC.50 This  directive  is  at  the  source  of  a  potential 
opposition between the rights of the patients and the right to 
patent an invention, similar to that between the rights of the 
patients and the copyright materials. Indeed Recital 26 of the 
Directive  provides  that  the  patient  who  has  given  biological 
material  that  has  served  as  the  basis  of  an invention in  the 
frame of a biobank, must give his free and informed consent as 
regards  the filling of  a patent  application on such invention, 
according to his national legislation. 
The  fact  that  this  measure  is  part  of  the  Directive’s 
introduction,  what  makes  it  an  ethical  rule  rather  than  an 
applicable provision, and the fact that several Member States 
did find it controversial and too advanced and therefore did not 
transpose  it  in  their  national  legislations,  does  not  solve  the 
problem that might occur if a patient would refuse to give his 
consent to the filling of a patent application for an invention 
made on the basis of biological material he gave.51
49  The spin-off  theory was developed in the Netherlands in the late 90’s and as already been examined 
by the European Court of Justice which adopted it in the case Fixtures Marketing Ltd v. Organismos 
pronostikon agonon podosfairou AE (OPAP), ECJ, 9th November 2004, 444/02, Rec., p. I-10549.
50  Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the protection of 
biotechnological inventions, OJ L 213, p. 13-21.
51  For details on this matter see « Intellectual property on medical data - chimaeras and actuality »,  
opcit, p. 753-755.
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2.4.9.What  about  Intellectual  Property  Rights  and 
healthgrids’ Components?
The  Directive  on  the  legal  protection  of  computer 
programmes 52 was a real European ‘first’ for copyright law. 
The  first  copyright  measure  to  be  adopted  following  the 
publication of the White Paper on completing the Single Market 
by  1992,  the  Directive  aims  to  harmonise  Member  States’ 
legislation regarding the protection of computer programmes in 
order to create a legal  environment that  affords a degree of 
security  against  unauthorised  reproduction  of  such 
programmes.
In  accordance  with  the  Directive’s  provisions,  the  Member 
States are obliged to protect computer programs by copyright, 
as literary works within the meaning of the Berne Convention 
for the Protection of Literary and Artistic Works.53
The  core  principles  of  the  Directive  state  that  a  computer 
program shall be protected if it is original in the sense that it is 
the author’s own intellectual creation, the author of a computer 
program  is  the  natural  or  legal  person  or  group  of  natural 
persons  who  created  it  and  where  collective  works  are 
recognised by the legislation of  a Member  State,  the  person 
considered  by  the  legislation  of  that  Member  State  to  have 
created the work is deemed to be its author54 or may be owned 
jointly.55 The  exclusive  rights  of  the  author  of  a  computer 
program include the right to perform or to authorise:
(a) the permanent or temporary reproduction of his computer 
program by  any  means  and  in  any  form,  in  part  or  in 
whole56; 
(b) the  translation,  adaptation,  arrangement  and  other 
alteration of his computer program and the reproduction 
52  Council Directive 91/250/EEC of 14 May 1991 on the legal protection of computer programs, OJ L 122, 
17 May 1991, p. 42–46.
53  Directive 91/250/EC on the legal protection of computer programs, art. 1(1).
54  Directive 91/250/EC on the legal protection of computer programs, art. 2(1).
55  Directive 91/250/EC on the legal protection of computer programs, art. 2(2).
56  Insofar as loading, displaying, running, transmission or storage of the computer program necessitate 
such reproduction, such acts shall be subject to authorisation by the copyright owner of the program.
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of the results thereof without prejudice to the rights of the 
persons who alters the program; 
(c) the  distribution,  including  the  rental,  of  his  original 
computer program or of copies thereof.57
Special  protection  measures  will  be  taken  against  a  person 
committing any of the acts listed hereunder:
(a) any act of putting into circulation a copy of a computer 
program knowing, or having reason to believe, that it is 
an infringing/a counterfeiting copy; 
(b) any possession for  commercial  purposes  of  a  copy of  a 
computer program knowing, or having reason to believe, 
that it is an infringing/ a counterfeiting copy; 
(c) any act of putting into circulation or the possession for 
commercial  purposes  of  any  means  with  the  intended 
purpose  of  facilitating  the  unauthorised  removal  or 
circumvention  of  any  technical  device  which  may  have 
been applied to protect a computer program.
The term of protection is granted for the life of the author and 
for  fifty  years  after  his  death  or  after  the  death  of  the  last 
surviving  author  in  the  case  of  collective  works.  When  the 
author  is  anonymous  or  has  used  a  pseudonym  or  where 
national legislation has appointed a legal person as the author, 
the  term  of  protection  runs  from  the  time  the  computer 
program is first lawfully made available to the public. Directive 
93/98/EEC on harmonising the term of protection of copyright 
57  On this point, it is important to underline that the Directive 91/250/EC foresees that the first sale in 
the Community of a copy of a computer program by the right holder or with his consent shall exhaust 
the distribution right within the Community of that copy, with the exception of the right to control 
further rental or the program or copy thereof.
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and certain related rights, extended the duration of copyright 
protection to seventy years.
A  further  piece  of  European  legislation  on  copyright  was 
adopted  in  2001  with  Directive  2001/29/EC  on  the 
harmonisation of certain aspects of copyright and related 
rights in the information society58, which sought to adapt 
legislation  on  copyright  and  related  rights  to  technological 
developments and particularly to the information society. The 
objective  was  to  transpose  at  Community  level  the  main 
international  obligations  deriving  from  two  Treaties59 
concerning copyright and related rights, adopted in December 
1996  in  the  framework  of  the  World  Intellectual  Property 
Organisation  (also  named  ‘WIPO’),  in  particular  concerning 
reproduction  rights,  the  right  of  communication  and 
distribution rights. 
2.4.10.Conclusion
Looking at the EU legislation around Intellectual Property Law 
and  its  application  to  healthgrids  we  have  seen  that  rules 
around protection of databases and computer programmes are 
poorly adapted to dealing with the open and shared nature that 
underlies the grid concept. 
A  Community-wide  harmonisation  of  the  national  legislations 
available  for  the  protection  of  copyright  and  certain  related 
rights  mainly  took place  through the legal  framework of  the 
Directive  on  the  Legal  Protection  of  Databases  mentioned 
above, which allows a harmonised protection of copyright and 
related rights in all the EU Member States. In this sense, the 
harmonisation  of  the  national  legislation  will  favour  the 
implementation  of  healthgrids  as  services  that  can  circulate 
freely  without  any  barriers  throughout  an  un-fragmented 
market.
58  European Parliament  and Council  Directive 2001/29/EC of  22 May 2001 on the harmonisation of 
certain aspects of copyright and related rights in the information society,  OJ L 167, 22 June 2001, p. 
10-19.
59  These two Treaties were the  WIPO Copyright Treaty and the WIPO Performances and Phonograms 
Treaty.
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On the other hand, copyrights can constitute an impediment in 
the  implementation  of  healthgrids,  given  that  copyright  law 
treats computer software as a copyrightable literary work, the 
same  as  a  play  or  a  novel.  The  copyright  owner  has  the 
exclusive right to reproduce his work, prepare derivative works, 
distribute copies to the public, perform the work publicly and 
display  the  work  publicly.  Under  these  circumstances,  any 
natural  or  legal  person  would  have  to  pay  to  use  computer 
programs  while  they  constitute  one  of  the  most  important 
compounds of healthgrids.
The open standards software approach could then be a solution 
to help the development and implementation of healthgrids. In 
the United States, the open source model (being a more open 
system  than  open  standards)  currently  uses  copyright  and 
contract principles to retain control of the work and could thus 
encourage  use  without  dedicating  the  work  to  the  public 
domain.60
60  See Dennis M. KENNEDY, “A primer on open source licensing legal issues: copyright, copyleft and 
copyfuture,  20  ST.  LOUIS  U.  PUB.  L.  REV.,  2001,  345,  p.  359-360;  David  MCGOWAN,  “Legal 
implications of open-source software”, U. ILL .L. REV., 2001, 241, p.242-243. More generally see Open 
Source Initiative, at http://www.opensource.org.
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3. ETHICAL CONSIDERATIONS – AN OVERVIEW
This  overview  of  medical  and  biomedical  ethics  is  to  give  a 
baseline  introduction  to  the  field.  This  baseline  of  ethical 
considerations will then be applied to healthgrids in subsequent 
deliverables,  and  the  links  with  legal,  social  and  economic 
issues made. 
3.1. INTRODUCTION
There  are,  of  course,  many  approaches  to  medical  ethics, 
ranging across religious, legal, philosophical and applied ethics, 
spanning many hundreds, if not thousands, of years of scholarly 
thought. One of the earliest statements on medical ethics - and 
certainly  the  most  quoted  -  is  the  Hippocratic  Oath.  Named 
after  the famous Greek physician Hippocrates,  this  oath was 
written  as  a  guideline  for  the  medical  ethics  for  doctors. 
Although the exact words have changed over time, the general 
content  is  the  same:  an  oath  of  respect  to  those  who  have 
developed the science of medicine, and a pledge of respect to 
the patients as well as the promise to treat them to the best of 
the one’s ability. Although the Oath is now not generally sworn 
at graduation ceremonies anymore, but has been updated and 
incorporated  in  to  modern  texts  such  as  the  Declaration  of 
Geneva and, in the United Kingdom, into the statement of the 
Duties of a Doctor as published by the General Medical Council.
 
The  first  formal  code  of  medical  ethics  to  be  adopted  by  a 
professional  organisation  was  written  by  English  physician 
Thomas Percival (1740-1804) in 1794 and adapted and adopted 
by  the  American  Medical  Association  in  1846.  This  code  of 
ethics,  which  provided  a  gold  standard  for  professional 
physicians,  dictated the moral  authority and independence of 
physicians in service to others and their responsibility towards 
the sick, as well as the physician’s individual honour.
While there are many differences in the labels used in medical 
ethics across the approaches, most agree on some fundamental 
aspects of ethical medical practice: the respect for the patient 
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as an individual, including a respect for his or her privacy; the 
duty to treat all patients equally and fairly; and the duty not to 
harm patients, either medically or through an abuse of power. 
One of the most well known and most frequently sited medical 
ethics  textbooks  is  Beauchamp  and  Childress’  Principles  of 
Biomedical Ethics  (Beauchamp, T and Childress L, 1979) first 
published in 1979 and now in its  fifth edition (2001).  In this 
book the authors set our four principle of ethical behaviour in 
medicine and biomedical science. In this section we will briefly 
explore those four key principles and consider the way in which 
the use of grid computing technology in health care might pose 





Beauchamp and Childress propose these four key principles as 
‘prima facie’ principles, meaning that they are binding unless 
and until they conflict with another ethical principle. At such a 
point, the two or more principles have to be weighed against 
each  other  and  the  most  ethically  imperative  one  must  be 
followed.  While  Beauchamp  and  Childress  do  not  offer  a 
formula for this weighing of competing values, it  is this skill 
which is most called upon in daily practice.
3.2. RESPECT FOR AUTONOMY 
Literally, autonomy means ‘self rule’, that is the ability to make 
our  own  decisions  on  the  basis  of  conscious  thought  and 
consideration. A basic principle of ethical medical behaviour is 
a  respect  of  such  autonomy  of  the  patient  by  the  medical 
professional in so far as such respect is compatible with equal 
respect  for  the  autonomy  of  all  potentially  affected.  Raanon 
Gillon  (Gillon,  R.  1994),  commenting  on  the  application  of 
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Beauchamp and Childress’ four principles in the British Medical 
Journal states: 
In  health  care  respecting  people's  autonomy has  many 
prima facie implications. It requires us to consult people 
and obtain their agreement before we do things to them -  
hence  the  obligation  to  obtain  informed  consent  from 
patients before we do things to try to help them. 
Respect for autonomy is usually listed as the first principle of 
medical ethics because it is believed to be the corner stone of 
good  practice.  It  will  require  even  mundane  administrative 
practice, such as keeping appointment times, since unless we 
respect such times we cannot respect  the right other people 
have to organise their lives as they see fit. 
It also requires good communication in order that patients have 
adequate information about any proposed intervention and also 
so  that  healthcare  professionals  can  establish  if  the  patient 
indeed  wants  that  intervention.  It  may  be  argued  also  that 
respect for autonomy includes respecting when patients do not 
want a lot of information; some patients do not want to be told 
about a bad prognosis  or to participate in deciding which of 
several treatments to have, preferring to leave this decision to 
their  doctors.  As  Gillon  argues,  “respecting  such  attitudes 
shows just as much respect for a patient’s autonomy as does 
giving patients information that they do want” (Gillon, R. 1994).
However, in daily medical practice a core aspect of the duty of 
respect  for  autonomy  is  the  duty  of  confidentiality.  It  is 
argued  that  showing  respect  for  a  person’s  autonomy  is 
respecting their right to privacy. Furthermore the promise to 
keep confidential issues revealed about why a particular choice 
is made is core to respecting that autonomy since an aspect of 
running our  own “life  depends  on  being  able  to  rely  on  the 
promises  made  to  us  by  others.  Without  such  promises  of 
confidentiality  patients  are  also  far  less  likely  to  divulge  the 
often highly private and sensitive information that is needed for 
their  optimal  care;  thus  maintaining  confidentiality  not  only 
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respects patients’ autonomy but also increases the likelihood of 
doctors being able to help them” (Gillon, R. 1994). 













In medical ethics the traditional ‘story’ used to illustrate this 
conundrum is the problem of treating the child of a Jehovah’s 
Witness  with  blood  products.  If  an  adult  Jehovah’s  Witness 
refuses treatment then it is generally accepted that he or she 
may continue to refuse treatment even if to do so would mean 
death, since a rational adult has a right to respect of his or her 
autonomy (in law imbedded in the requirement for consent to 
treatment) and thus the doctor would not be entitled to override 
the adult’s refusal even if to do so would save his or her life. 
In the case of a child, however, the situation is different. A child 
is  not  accorded  the  same  respect  for  autonomy  and  while 
generally  the  consent  of  the  adult  responsible  for  a  child  is 
required  to  treat  a  child  a  refusal  of  such  consent  can  be 
overridden if the child will be significantly harmed. As a result 
we have, in jurisdictions across the European Union, provision 
for the courts to make order to treat a child notwithstanding the 
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parent or guardian’s refusal of consent. In such a case therefore 
beneficence/non-malfeasance overrides autonomy. 
Thus we see that in both in philosophical ethics and in practical 
ethics  we  have  established  an  ethical  duty  of  respect  for 
autonomy, which is balanced against the duty to do good  - or at 
least to do no harm. The nature of the balance is determined by 
the power of the parties involved. 
A further problem in  medical  care will  arise,  however,  when 
individual  care  is  balanced  against  public  good  –  when  the 
respect for one person’s autonomy may lead to harm to another 
or  harm  to  the  fabric  of  our  society.  The  balance  of  these 
competing  ethical  principles  is  often  exercised  through  law, 
creating  Public  Health  legislation  which  call  for  compulsory 
reporting and treatment of certain diseases (e.g., tuberculosis, 
cholera)  even  when  to  do  so  would  breach  a  patient’s 
confidentiality and right to refuse treatment.
3.4. JUSTICE
In  the  balance  of  individual  rights  and  benefits  against  the 
rights of others and the public good, we embrace the ethical 
principle  of  justice.  The  obligation  to  produce  net  benefit, 
however,  must  also  require  us  to  define  whose  benefit  and 
whose harms are likely to result from a proposed intervention, 
and to consider these benefits within the bigger picture of a fair 
and just  resource allocation.  This  problem of  moral  scope is 
particularly  important  in  medical  research  and  population 
medicine. 
No  ethical  model  will,  of  course,  be  bale  to  solve  those 
problems,  their  role  is  instead  clarifying  their  existence  and 
highlighting the need to find balance wherever possible among 
competing needs.
3.5. ETHICS IN EHEALTH
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Despite the fact that information technology has been used in 
the  delivery  of  healthcare  for  well  over  20  years  now  and 
despite the fact that all Member States of the European Union 
have  now adopted  eHealth  plans,  remarkably  little  has  been 
written  about  the  ethics  of  using  these  technologies  in 
healthcare. One of the most abiding works is still that of Rippen 
and Risk published in 2000, which led to the adoption of the 
Internet Health Coalition’s eHealth Code of Ethics.  









The code is targeted at the provision of information via the Internet, 
rather than the use of information technologies directly in the care of 
patients and in professional decision-making. The emphasis is thus on 
ensuring that the consumer of a health related website knows where 
and how information for the site was obtained, why it is provided and 
to  ensure  that  those  providing  such  information  to  patients  are 
responsible in their choice of partners and are ultimately accountable 
to  the  consumer  for  the  information  available  on  the  site.  These 
concepts are reflected in nearly all statements of good health websites 
practice,  including  the  Health  on  the  Net  Code 
(http://www.hon.ch/HONcode/)  the  European  Commission’s 
Communication  on  Quality  Criteria  for  Health  related  Websites 
(COM(2002)667).
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4. ECONOMIC ANALYSIS FOR HEALTHGRID PLANNING
4.1. INTRODUCTION
Legal and regulatory issues are only one side of the non-technological 
challenges to implementing healthgrid based solutions in Europe. If 
we are really to plan effectively to get the most out of this technology, 
we need a thorough understanding of the economic and social drivers 
that  might  impact  on  the  uptake  of  healthgrids.  In  the  following 
section we therefore look at the factors that a thorough healthgrid 
roadmap should take into account if it is to be effective in supporting 
further development and ultimately uptake of grid based computing in 
the health sector.
Economic  theory  and  practice  is  essentially  concerned  with  the 
optimal  allocation of limited resources that have  alternative uses61. 
Resources  are goods and services, which represent means towards 
an end – ultimately the satisfaction of the needs and wants of human 
beings,  citizens  in  our  society.  It  is  often  thought  that  economic 
analysis focuses only on perfect market mechanisms, where needs or 
wants are articulated as demand for physical goods and services in 
complete  markets  with  competing  suppliers  and  where  trade  and 
pricing are closely related. This, however, is not the case. Much of 
modern  economic  theory  focuses  on  so  called  failures  of  the 
market. These include cases of imperfect and incomplete information 
in  the  marketplace,  externalities  and public  goods,  markets  where 
competition  is  restricted,  and  resource  allocation  by  mechanisms 
other than trading in markets. These are all features of the healthcare 
sector, requiring us to look in detail at such aspects as stakeholder 
groupings,  their  goals  and  incentives,  like  the  benefits  flowing  to 
them.
However, before setting out the basic economic analysis tools which 
may be used in assessing healthgrids we need to define some key 
terms. Accordingly we will begin by looking at the prime objectives of 
a healthcare system and the roles of key actors in such systems with 
respect  to their  interests  in and impact  on the potential  uptake of 
healthgrids, and the main externalities affecting healthgrids. 
61  Dernburg TF, McDougall DM: Macroeconomics (3rd edition), New York: McGraw-Hill, 1968, p. 
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4.2. PRIME OBJECTIVES OF A HEALTHCARE SYSTEM
Although the Member States of the European Union have a variety of 
different approaches to health services organisation and regulation, 
all  EU  health  systems  aim  to  ensure  healthcare  provision  that  is 
“patient-centred and responsive to individual need”62. 
All  the  Member  States  also  aim to  making  the  systems  financially 
sustainable,  while  simultaneously  safeguarding  the  core  values  of 
healthcare: 
• Quality  is  achieved  through a  range  of  measures.  In  particular, 
providing  high  quality  healthcare  is  a  function  of  continuous 
training of staff according to accepted standards, dissemination of 
good practices and innovative knowledge, as well as monitoring and 
good clinical governance.
• Safety  refers to a systematic approach to ensuring patient safety, 
including the management of risk factors. This includes adequate 
training for health professionals and protection against misleading 
information about health and healthcare.
• Care  that  is  based  on  evidence  and  ethics is  essential  for 
providing high-quality  treatment and ensuring sustainability  over 
the long term. A primary ethical challenge is to balance the needs 
of individual patients with the financial resources available to treat 
the whole population.
• Involving the patient includes transparency of healthcare status, 
treatment  procedures,  options,  and  choices,  as  well  as  active 
participation of the patient in making these choices.
• Redress:  “Patients  should  have  a  right  to  redress  if  things  go 
wrong.  This  includes  having  a  transparent  and  fair  complaints 
procedure, and clear information about liabilities and specific forms 
of  redress  determined  by  the  health  system  in  question  (e.g. 
compensation)” .63
• Privacy and confidentiality, as protected by national legislation 
and international law.
62 ”  Council  Conclusions  on  Common  values  and  principles  in  European  Union  Health  Systems”, 
Document (2006/C 146/01), Official Journal of the European Union on 22 June 2006, pp. 1 - 5
63 ibid.
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Grid  technologies,  by  allowing  for  more  comprehensive  and  faster 
creation, monitoring, and update of the medical content of prevention 
and health promotion schemes, are expected to play an important role 
in creating more efficient, patient-centred systems of healthcare that 
are able to sustain those core values. It is important therefore that in 
order to understand the potential of healthgrids and in order to adopt 
sensible roadmaps for research on grids and their implementation in 
the health  sector  that  we understand the key  legal,  economic  and 
socio-organisational issues that are to be addressed. 
If  health is  defined according to the WHO as a “state of complete 
physical, mental and social well-being and not merely the absence of 
disease  or  infirmity”64 it  should  be  possible  to  derive  directly  or 
indirectly all of the following health system tasks and objectives from 
the overall  objective of  delivering health  efficiently,  and healthgrid 
applications  can  usefully  be  assessed  against  their  contribution  to 
each:
• to improve health outcomes;
• to protect patient safety;
• to cope with rising demand from ageing populations and increased 
expectations;
• to  make  healthcare  access  more  egalitarian,  ensure  equality  of 
access across social strata and at-risk groups, older people, regions 
of countries and the Union; 
• to  accelerate  innovation:  translation  of  new  research-based 
knowledge into practice;
• to  improve  public  health:  disease  control,  surveillance  and 
preventive measures;
• to protect the public against bio-terrorism and other new threats;
• to accelerate knowledge creation in research (medical, bio-medical, 
pharmaceutical, medico-technical, bio-informatics and ICT);
• to improve the quality of services;
• to reduce errors, duplicative and inappropriate care;
64  Preamble to the Constitution of the World Health Organization as adopted by the International 
Health Conference, New York, 19-22 June, 1946; signed on 22 July 1946 by the representatives of 61 
States (Official Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 
April 1948 (see: http://www.who.int/about/definition/en/
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• to  augment  knowledge  and  capabilities  of  healthcare  staff 
(continuous professional development);
• to improve quality of life perceived by patients;
• to  improve  quality  assurance  in  hospitals  and  other  health  and 
social care providers;
• to  manage  citizen  (patient)  mobility  and  the  free  movement  of 
professionals;
• to contain costs;
• to  allocate  resources  optimally  according  to  commonly  agreed 
health policy priorities;
• to make best use of private service providers, international hospital 
chains, private equity, cross-border cooperation.
4.3. KEY ACTORS IN HEALTHCARE SYSTEMS
An essential part of any social and economic analysis of the potential 
impact  of  a  new  policy  package  is  an  assessment  of  the  key 
stakeholder groups who could have an impact on acceptance of policy 
and  implementation  of  new  healthcare  models.  It  is  important 
therefore to identify who the key actors  are,  what their  respective 
costs and benefits in the execution of any new policy package might 
be,  and  which  facilitators  and  barriers  may  exist  towards 
implementation and diffusion of new ICT-based solutions.
Based on a  typology  of  actors  and roles  relevant  in  health  system 
activities developed by the eHealth ERA project65, the following is an 
illustrative  list  of  possible  actors  and  stakeholders  in  healthgrid 
applications:
• Healthcare provider organisation: an organisation, or part of 
such, engaging in healthcare activities. A self-employed doctor 
or other person is an organisation in this sense.
• Healthcare  professional:  an  employee  of  a  healthcare 
provider organisation.
• Healthcare organisations (organisations employing personnel 
providing  specific  healthcare  services  to  patients):  Health 
centres,  hospitals,  emergency  services,  imaging  centres, 
65  www.ehealth-era.org 
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laboratories,  pharmacies,  doctor,  dentist,  midwife,  nurse, 
chiropodist.
• Public health bodies (epidemiology data gatherers - for health 
information  see  healthcare  information  providers):  European 
Commission, WHO, Ministries of health, local government.
• Healthcare  information  and  knowledge  providers 
(organisations  and  individuals  authoring  and/or  publishing 
electronically  or  on  paper  information  about  healthcare  and 
medical  knowledge  for  citizens,  patients  and  healthcare 
personnel):  include  universities  and  colleges,  publishers, 
authors, editors, web-site providers; and research organisations.
• Healthcare  suppliers  (organisations  trading  in  goods  and 
services that enable provision of specific healthcare services but 
are  not  themselves  specific  healthcare  services):  include 
pharmaceutical companies, providers of medical equipment, ICT 
suppliers, and pharmacies.
• Healthcare  policy-makers:  ministries  of  health,  local 
authorities,  municipalities,  World  Health  Organisation, 
European  Institutions  (e.g.  European  Commission  DG  Health 
and Consumer Protection).
• Healthcare insurers (bodies acting to insure and compensate 
for  or reimburse costs  for individual  patients):  include public 
health  insurances,  private  health  insurances,  and  national 
health services.
• Doctors  include  those  individual  roles  in  the  provision  of 
specific  healthcare  services  usually  requiring  a  medical 
doctorate  including  physicians,  gynaecologists,  surgeons, 
oncologists, anaesthetists, paediatricians, dentists, ... 
• Nurses:  individuals  with  nursing  qualifications,  whether 
working  as  community  nurses,  in  doctors'  surgeries  or  in 
hospitals.
• Healthcare ancillary staff: healthcare location managers and 
administrators, porters, cleaning staff, and others.
• Other healthcare personnel: midwives, paramedics...
• Patients: individual citizens having suffered an injury or attack 
of an illness and before that illness or injury is fully cured; or, 
more  generally:  citizens  having  suffered  a  health-threatening 
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event and before the impact of that event has been eliminated / 
has become irrelevant.
• Citizens  not  (yet)  suffering,  but  being  affected  by 
environmental  risks,  health  promotion,  knowledge  about 
diseases  and  their  prevention,  requiring  information  about 
health lifestyles …
• Self-helping citizens: Patients and other citizens operating in 
the  role  of  healthcare  personnel  (determining  medication, 
monitoring vital signs, monitoring for signs of illness...)
• Informal  carers:  private  citizens  not  necessarily  formally 
educated in healthcare providing specific healthcare services to 
one or more patients.
• Insurances and other third party payers,  whether within a 
social insurance system or in a complementary private system.
This typology is designed as a typology of actors and roles rather than 
stakeholders,  the  economic/payer  view  is  therefore  perhaps 
underrepresented.  We  may  need  to  add  the  roles  of  taxpayer  and 
insurance  premium  payer  among  others.  Though  these  roles  may 
coincide  with  “patient”  or  “self-helping  citizen”  in  the  same 
individuals at any time, this is certainly not always the case, and any 
analysis should maintain these stake holdings as distinct.
In  evaluating  healthgrid  applications,  an  appropriate  values 
perspective  is  that  of  the  social  planner,  taking  all  actors  and 
stakeholders into account. At the same time attention should also be 
paid to how incentives can be provided to ensure investment actually 
goes  ahead in  cases  where  cost  and benefit  flows are  to  different 
stakeholder  groups,  and  where  the  financial  benefits  that  usually 
guide decision makers are not sufficient. 
For the particular case of healthgrid technologies, an important issue 
in  this  respect  is  the  fact  that  an  organisation  is  providing  its 
resources  all  the  time,  but  only  accessing  resources  for  limited 
periods.  With  competition  in  the  R&D  sector,  for  example,  where 
payoffs  and  risks  are  high,  some  organisations  may  not  have  an 
incentive  to  cooperate  because  of  the  further  increased  risk  of  a 
competitor being first in an invention who might, through the use of a 
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healthgrid system (for example in drug discovery) use resources of a 
‘loser’ for his own gain. 
4.4. IMPORTANT EXTERNALITIES IN ASSESSING 
HEALTHGRIDS
In economic analysis, externalities are defined as the impact of actor 
A’s activities on actor B, who is not directly involved in that activity. 
Externalities are a particularly important feature of healthcare and a 
source of serious market failure66. For example, when a doctor invests 
in a new diagnosis support instrument, he probably takes into account 
the effects on his work,  such as less time spent on diagnosis,  and 
probably  on  the  patient  insofar  as  patients  are  more  satisfied. 
However,  the  investment  has  a  much  larger  impact  –  from  the 
insurance company, which may see its expenditures reduced because 
illness is discovered at an earlier stage, to an increase in the total 
output  of  the  economy due to  the associated  decrease  in  sickness 
leave.  The  problem  faced  by  classical  economic  evaluation  and 
assessment methods is that there is no market for, and thus no price, 
for an externality67. What is often referred to as broader effects on 
society  and  the  economy68 are,  from  an  economic  point  of  view, 
externalities in one form or another. 
In a market setting it is usually the main beneficiary of a service who 
pays, and investments are only made if adequate returns accrue to the 
party  making  the  investment.  In  healthcare,  flows  of  benefits  may 
diverge from flows of costs. In particular, studies show that patients 
can  benefit  extensively  from  eHealth  applications,  but  healthcare 
providers are often the main entity financing eHealth investment69. 
"Private" benefits to providers may not provide sufficient incentive in 
respect of these investments, whose social benefits may nevertheless 
66  For a good introduction see Varian, H.R.: Intermediate Microeconomics: A Modern Approach, 
6th ed., Norton, 2002
67 This is the definition of externality. The most common examples of externalities are negative – like the 
environmental damage from a factory having an impact on a biological products farm. Here we are 
dealing mostly with positive externalities. 
68 For example in a recent report by the UK Evaluation Forum “Medical research: assessing the benefits 
to society” (2006), 
69 Jones T (2003) e-Health - Financial and Economic Case Studies, ACCA (The Association of Chartered 
Certified  Accountants)  with  the  European  Commission  DG INFSO,  http://www.accaglobal.com/pdfs/ 
members_pdfs/publications/m-eh-001.pdf
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constitute a very substantial return to society as a whole. More recent 
evidence70 shows two no less important issues: 
• the  benefits  are  often  non-financial,  which  thwarts  eHealth 
investments that should be made from an economical point of view; 
• many  potential  investors,  in  particular  healthcare  provider 
organisations,  do  not  realise  what  the  scope  of  the  benefits  to 
themselves is.
4.5. A SIMPLE ECONOMIC AND SOCIAL ISSUES ANALYSIS OF 
HEALTHGRIDS
Having established the key stakeholders and primary objectives and 
externalities relevant to an understanding of healthgrids, we can now 
outline  a  simple  economic  analysis  of  the  potential  impact  of 
healthgrids.  Like  in  our  assessment  of  the  legal  and  regulatory 
aspects of healthgrids, the aim is to provide a baseline of common 
information against which a roadmap that highlights the bottlenecks 
and  challenges  to  the  implementation  of  healthgrids  can  be 
developed. 
Socio-economic  evaluations  of  healthgrid  applications,  as  of  other 
areas  of  eHealth,  can  help  provide  evidence-based  information 
enabling  them  to  identify  appropriate  targets  for  investment,  and 
specifically to identify:
• type  and  scope  of  benefits for  patients,  carers,  healthcare 
professionals,  healthcare  provider  entities  and  other 
stakeholders  in  taking  decisions  to  invest  in  eHealth 
applications;
• de facto beneficiaries and cost bearers of eHealth;
• number  and  type  of  users,  their  levels  of  utilisation,  and  so 
required and future capacity;
• impact on meeting demand;
70  eHealth IMPACT: Study on the economic impact of eHealth, commissioned by the European 
Commission DG INFSO; http://www.ehealth-impact.org. For a summary report, see Karl A. Stroetmann, 
Tom Jones,  Alexander Dobrev,  Veli  N.  Stroetmann:  eHealth  is  Worth it  -  The economic benefits  of 
implemented eHealth solutions at ten European sites. Luxembourg: Office for Official Publications of 
the  European  Communities,  2006  (56  pp.  -  ISBN  92-79-02762-X).  Electronic  file: 
http://europa.eu.int/information_society/activities/health/docs/publications/ehealthimpactsept2006.pdf
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• enabling  changes that  become  possible  to  introduce  new 
healthcare models and regional provider networks;
• benefits for clinical audit and governance;
• impact  on  established  organisations,  their  structures, 
hierarchies, and workflows;
• scale of the critical investments needed in training and change 
management;
• potential changes to the costs of providing healthcare and the 
potential to generate additional income;
• impact  on  the  future  ICT  infrastructure  needed  to  support 
eHealth;
• impact on third party payers.
Evaluation can help remove inhibitors,  show best  practice,  support 
future  investment  decisions  and  create  enablers  for  change  in 
eHealth. This is particularly important in Europe today, where eHealth 
is far from having become an integral part of routine medical service 
processes,  beyond  support  for  basic  administrative  processes  or 
isolated applications in hospitals, medical labs and the like. In recent 
comprehensive empirical European market studies, it was shown that 
diffusion  of  advanced  applications  is  still  very  limited  or  entirely 
lacking.  The  lack  of  reliable,  transferable  empirical  evidence  of 
eHealth  effectiveness  and  outcomes,  and  of  its  cost  and  benefit 
efficiency, is widely seen to be a significant part of the problem. 
However, even if fully reliable and validly transferable evidence shows 
a positive rate of return on investment (ROI) for eHealth, this will not 
be sufficient to convince many health system stakeholders. Besides 
reliable,  easy  to  use  technology  and  positive  outcomes  in  medical 
and/or financial/economic terms, the policy and organisational aspects 
of the processes of implementation, change and diffusion can take on 
a more significant, and unfortunately often hindering aspect. 
Organisational and systems views are important. Readiness, training, 
acceptance by all, win-win situations for all stakeholders, are some of 
the  additional  factors  that  will  impact  on  the  process  of  eHealth 
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implementation and diffusion.71 These factors must be known in order 
to analyse the effect of using new technologies like healthgrids. 
However, robust analyses of the effects of using new technologies are 
rare and nearly non-existent with respect to healthgrids72. Identifying 
the positive as well as negative impact of such new technologies and 
in particular the benefits from using them is critical to building an 
environment  of  well-informed  decision  making  and  successful 
implementation of beneficial technological solutions.
4.6. ECONOMIC ASSESSMENT MODELS / APPROACHES
There are a number of economic analysis techniques and metrics that 
are applicable  to eHealth  evaluation and analysis.  The mainstream 
economic analysis techniques and models most relevant for eHealth 
applications evaluation are:
• Cost benefit analysis (CBA) (quantitative, monetary scale)
• Cost utility analysis (CUA) (qualitative scale)
• Cost effectiveness analysis  (CEA) (achieving the best possible 
outcome for a given [fixed] cost)
• Cost  minimisation  analysis  (CMA).  (minimising  the  costs  of 
achieving a fixed outcome)
71  May C et al. (2003)  Why do telemedicine systems fail to normalize as stable models of ser-
vice delivery?  Journal of Telemedicine and Telecare 9 (Suppl. 1):25-26
72  The  ‘Joint  White  Paper  from  the  healthgrid  association  and  Cisco  Systems’  “HEALTHGRID  –  A 
SUMMARY”, (http://whitepaper.healthgrid.org) for example states even that there are indeed very few 
“cases that  demonstrate the benefits  of  dramatically  new technologies (like GRID)”. The economic 
analysis accompanying most of these few cases is very limited.
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The following supporting techniques and measures are both used in 
the above types of analysis or may provide independent metrics for 
economic assessment:
• Marginal Net Present Value calculation (MNPV)
• Discounting (Present Value calculations)
• Payback period and breakeven point analysis
• Affordability gap analysis (AGA)
• Utilisation review (UR)
• Value chain analysis (VCA)
• eHealth utilisation (EHU) analysis
• Different approaches to costing
• Taking into account contingencies and risks.
Key methods and approaches are summarised as follows:
Cost  benefit  analysis is  a  measure  of  economic  or  monetary 
allocative  efficiency.  It  identifies  and  measures  the  total  costs  and 
benefits of a project, which may include social costs and benefits, in 
monetary values. These are discounted to a net present value (NPV) to 
reflect the opportunity cost of time. The resulting discounted costs 
and benefits can be presented as a benefit/cost ratio, or as the value 
of  net  benefits  (total  net  present  value  of  benefits  minus total  net 
present  value  of  costs).  Where  a  number  of  options  are  being 
evaluated,  these  can  be  compared  in  order  to  identify  the  most 
profitable option. A key methodological issue is how to affix monetary 
values to individual and societal benefits.
Cost  utility  analysis is  a  measure  of  technical  and  allocative 
efficiency. It measures the cost of a particular treatment or type of 
care and compares it to the effects, expressed in additional utility to 
the patient. Utility can include anything from a subjective feeling of 
satisfaction to objective factors such as being alive and not suffering 
illness. Often, Quality Adjusted Life Years (QALY) are used as a unit of 
utility.  Comparing  the  costs  per  additional  QALY  allows  decision 
makes to identify the investment option that increases patient’s utility 
the most, given the resources available.
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Cost effectiveness analysis  is a measure of  technical efficiency. It 
identifies and measures the costs of different options for achieving a 
required outcome. Alternatively, this is the same as the option that 
delivers maximum output at a given cost. In contrast to a CBA, one 
part of the input/output ratio has to be fixed.
Cost minimisation analysis is a variant of cost effectiveness where 
all outcomes are set as equal. It identifies and measures the changes 
in unit costs to a healthcare provider that arise from a specific group 
of activities.
Discounting (Present Value calculation) is the technique by which 
monetary  values  from  different  points  in  time  are  converted  into 
comparable measures. Usually, it is absolute monetary values in the 
future that are reduced in order to show their value at present – thus 
accounting  for  the  opportunity  cost  of  time  (interest,  utility  from 
consumption  now  instead  of  later,  risk,  etc.).  Discounting  is 
particularly important in evaluating long-term investments where the 
benefits  (returns)  arise  much  after  the  point  of  investment 
expenditure. It also enables costs of projects with different life cycles 
to be compared.
Net present value identifies and measures the economic return to a 
commercial, private entity, from a specific investment in resources to 
achieve improved performance. It is discounted at the organisation’s 
cost of capital to reflect the time value of money.  It is a decision tool 
for  the guidance of  private  investors  who seek to  rank projects  in 
order of their profitability.
Payback  period  and  breakeven  point reveals  the  time  that  an 
entity has to wait to recover its investment in a project. It relies on the 
relationships between estimated cash flows going out of, and coming 
into a project. It disregards cash flows beyond the payback point. Its 
limitations as a measure are compensated by the need to ensure cash 
flows from a project are successful and that the inherent, increased 
risk of future cash flows are managed effectively. The payback period 
is the time span from the start of a project to its breakeven point (the 
point in time where cumulative income just covers cumulative costs). 
Breakeven analysis can also refer to a single time unit (like a year). In 
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that  case  it  measures  whether  expenditure  is  covered  by  income 
within that particular year.
eHealth utilisation analysis identifies and measures the extent to 
which, and when, an eHealth investment is used over time. It can be 
applied  at  the  point  of  care  and  at  the  link  between  healthcare 
professionals and their teams. It relies on data of transaction volumes 
for the eHealth application, and reflects acceptance, appropriateness 
and impact, and can be used to test the relative timing of eHealth cost 
and benefit curves.
Types of costing tool The main types are variable and fixed costing, 
total absorption costing, and activity based costing.
Types  of  cost:  Variable  costs  vary  directly  with  the  numbers  of 
patients.  Fixed costs are commitment to expenditures that remain 
exactly the same for any volume of patients over the specified time 
horizon. There is also a classification of  semi-variable costs. These 
change  with  stepped  changes  in  volume,  and  can  be  the  most 
important to identify. There are likely to be several semi-fixed costs 
for an eHealth application that covers several healthcare groupings. 
Variable costing can also be used to measure costs where eHealth 
results in a benefit that is in effect a change in costs. This could be 
fewer  journeys  by  patients,  making  a  benefit  of  the  eHealth 
intervention, or a reduction in travel costs. Another example is where 
an eHealth application means that fewer pathology tests are carried 
out for a patient. The small reduction in costs e.g. of chemicals and 
reagents can be captured using variable costing. Where a change in 
the number of patients occur, say due to improved access, then the 
variable costs would change for a raft of resources, such as drugs, 
test consumables and medical supplies.
Activity based costing: Some years ago, the rigour of apportionment 
to types of cost was challenged73 and the concept of activity based 
costing (ABC) introduced. ABC sought to improve the apportionments 
in total absorption costing by identifying and applying cost drivers. It 
also  proposed  that  costing  models  should  be  extended  beyond  the 
73  Relevance Lost The Rise and Fall of Management Accounting. H Thomas Johnson, Robert S 
Kaplan, Harvard Business School Press, Boston Massachusetts 1987
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entity so that knock-on cost changes could be included in the costing 
model.  Our  experience  is  that  activity  based  costing  concepts  are 
valuable  in  the  productivity  evaluation  of  eHealth.  However,  its 
application tends to be costly and therefore in any specific decision 
setting the cost of  improving information quality this  way must be 
weighed  against  the  possibly  marginal  value  of  increased  decision 
certainty.
Contingencies in this setting are for correcting optimism bias and 
the  impact  of  estimated  risks  on  measurements  and  outcomes. 
Evaluations  have  a  tendency  to  understate  costs  and  overstate 
benefits. This increases where the basis of estimates relies more on 
judgement than facts and where the person making the judgement 
has an incentive to overestimate performance.74
4.7. APPLYING THE EHEALTH IMPACT METHODOLOGICAL 
FRAMEWORK TO HEALTHGRIDS
Clearly,  when  considering  the  wide  variety  of  methodological 
approaches  and  options  available,  a  choice  has  to  be  made.  The 
review undertaken and our assessment of the usefulness of various 
methods  identified led  us  to  conclude to  make use of  the eHealth 
IMPACT75 approach. It was developed as part of the eHealth IMPACT 
study  which  assessed  ten  successful,  sustainable  eHealth  solutions 
across the full spectrum of potential application areas, and it is being 
used for evaluating further eHealth solutions. These range from an 
electronic health record system to nation-wide exchange of medical 
messages or supply chain management.  The methodology needed for 
the  eHealth  IMPACT  study  was  identified  and  developed  from  a 
focused review of state-of-the-art of economic evaluation techniques 
and assessments of ICT applications in healthcare and beyond.  CBA 
(Cost  Benefit  Analysis)  became the  preferred  economic  concept. 
The  intentionally  generic  nature,  flexibility  and  adaptability  of  the 
methodology to specific instantiations of the wide variety of eHealth 
solutions allow the economic evaluation and assessment of the use of 
grid technologies in health services, including research.
74  HM Treasury, www.hm-treasury.gov.uk London, 2003
75  www.ehealth-impact.org
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The  eHealth  solution  to  be  assessed  is  approached  from  a  socio-
economic perspective, comprehensively identifying all relevant costs 
and  all  major  benefits  for  all  stakeholders:  citizens/patients, 
healthcare provider organisations, and third party payers. The method 
focuses on measuring  net economic gains: the difference between 
the  economic  values  of  direct  benefits  minus  the  identified  costs; 
eHealth  utilisation,  defined  as  the  usage  of  the  service  that  is 
supported  by  ICT;  and  productivity.  Productivity  is  measured  by 
changes in the unit cost of the service provided. Economic variables 
are  followed  through three  periods  in  the  lifecycle  of  the  eHealth 
application: planning and development, implementation, and routine 
operation. The method can be used both for ex-post evaluation and ex-
ante  assessment  based  on  past  experience  and  forecasts  of  future 
values.
Costs are divided into two main categories:  investment costs  and 
costs of running the healthcare related service. eHealth investment 
includes initial and replacement costs for ICT hardware and software, 
and costs of process and organisational change. Change management 
resources  are  a  critical  factor  in  benefits  realisation.  Operational 
costs include mainly staff costs, for professionals and support staff, 
and related other healthcare process costs. Costs are analysed by how 
they change as a result of the eHealth investment, both increases and 
reductions  over  time.  Benefits  are  identified  from  the  respective 
stakeholder  groups  involved.  They  cover  three  main  categories: 
quality,  access  and  efficiency.  Quality  includes  the  following 
subcategories:  informed  citizens,  patients  and  carers;  information 
designed  around  the  citizen;  timeliness  of  care;  safety;  and 
effectiveness. 
For  the  concrete  case  of  healthgrid  applications,  the  following 
examples  illustrate  some  intuitive  benefit  factors  and  potential 
methods of estimating their monetary value.
• Time savings from faster access to database search results, due to 
more computer power. The value of this can be calculated using the 
pay rate of staff doing the search. This would only apply to searches 
within databases accessible without the grid application.
• Access for professionals to larger, or joined, clinical and research 
databases  for  clinical  purposes.  The  value  can  be  estimated 
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using  data  on  the  frequency  of  access  and  change  the  clinical 
results due to the availability of this additional data.
To allow for an economic assessment, all benefits must be assigned a 
monetary value. Where no market prices, prices inferred from similar 
contexts or monetary values of time saved etc. are available,  other 
estimations  are  required;  these  are  always  based  on  conservative 
assumptions. Willingness to pay (WTP), inferred from behaviour, is a 
common  and  accepted  estimation  method  also  used  in  eHealth 
IMPACT evaluations for the monetary value of intangible benefits that 
have  no  market  price.  All  monetary  values  are  converted  into 
comparable measures by presenting them in present values.
The extensive use of estimated values, indispensable for a pragmatic 
approach to measuring the past, and particularly the future impact of 
eHealth,  requires adjustments for optimism bias and contingencies. 
The size of the adjustment depends on the availability and quality of 
the  actual  estimates.  A  sensitivity  analysis  further  helps  test  and 
verify the results for possible weakness of the available data.
The eHealth IMPACT methodology was tested and refined on ex-post 
evaluations, due to pragmatic reasons of data availability.  However, 
the design allows equally for ex-ante assessments of the impact of 
investing  in  ICT  in  health  services,  the  risks  involved,  and 
identification  of  key  success  factors.  Given  the  limitation  of  funds 
available to health systems, such assessment is critical for achieving 
optimal allocation of resources.
The experience and results  from the 10 evaluations undertaken as 
part  of  the  eHealth  IMPACT study,  and the preliminary indications 
from two extra studies, can be taken forward to a business case for 
investment  in  eHealth.  Of  course,  additional  aspects,  like  financial 
analysis, affordability, and risk have to be taken into account, yet the 
generic  economic  case  for  future  eHealth  investment  can  be 
constructed  using  the  knowledge  from  eHealth  IMPACT.  In  the 
concrete  case  of  healthgrid  in  health  services  and  research,  this 
would, however, be a highly complex and time consuming task. 
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5. GENERAL CONCLUSION - HIGHLIGHTING THE POTENTIAL 
LEGAL AND ECONOMIC BOTTLENECKS FOR 
HEALTHGRIDS IN EUROPE 
The preceding pages have set out in some detail the existing EU level 
legal  tools  as  well  as  economic  principles  which  are  important  in 
understanding the potential bottlenecks for healthgrids in Europe. 
In  the  section on legal  issues,  we looked at  legislation concerning 
Data  Protection,  Liability  for  Goods  and  Services  and  Intellectual 
Property  Rights.  In  the section on economic issues,  we considered 
wider social values of health and health systems and the key actors 
with  social  and  economic  interests  in  such  systems.  We  then 
considered the common economic tools used to assess the economic 
value in health and in particular in eHealth -we ended by looking at 
the value assessment model proposed in the eHealth IMPACT study.
Looking back at the discussion on Data Protection we can see that in 
broad terms the current EU level legislation is adequate but not ideal 
for promoting healthgrids. The discussion of the basic concepts and 
duties of the Data Protection Directive and its impact on healthgrids 
shows  that,  when  healthgrids  are  used  for  treating  patients  or 
planning care,  the requirements of  the  legislation provide that  the 
data are collected and processed by medical  professionals  and the 
balance of rights weighs in favour of data collection – that is, it  is 
assumed that the patient’s general interest in obtaining treatment or 
advancing medical care outweighs his interests in privacy. 
The current legislation is not, however, adequate to support most of 
the longer running research initiatives around which healthgrids are 
based. As the current EU level legislation stands, Member States can 
enact specific legislation covering specific tools such as healthgrids in 
order to exempt scientists and medical practitioners using healthgrids 
from some of the more onerous duties of the Directive. 
Member  States  could,  for  example  adopt  specific  legislation  to 
encourage the linking of diagnosis specific databases across a region 
or state in order to support research into a given disease. However, to 
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date,  no Member  State has  addressed legislation to  this  particular 
issue and so healthgrids drawing the data and data processing power 
of  many  hospitals  are  burdened  with  onerous  data  protection 
requirements  which  could  deter  scientists  from  using  adopting 
healthgrid technology and using its enhanced computational and data 
acquisition power.
The examination of the EU level legislation on Liability for Goods and 
Services shows that it is not at all adapted to the healthgrid domain. 
One of  the  reasons  for  this  is,  of  course,  that  health  services  are 
organised at national or regional level and that the European Union 
has no legal competence to draw up legislation that states specifically 
how a health service should be organised.76
However, the EU does have a range of legislation designed to protect 
citizens from harm resulting from goods offered on the market. Steps 
could  be  taken  using  guidelines,  or  even  specific  legislation,  to 
address  distributed computing services,  such as healthgrids,  which 
would seem at present to be only marginally covered by the existing 
rules.  Accordingly  it  is  important  that  the  existing  European 
framework of general product safety is re examined to consider its 
applicability to distributed networks such as healthgrids. 
Furthermore, the law on medical devices is very unclear with respect 
to healthgrids:  while  it  may be argued that  a healthgrid could fall 
within the ambit of the current Medical Devices Directive in that it is 
a software tool that impacts on a medical act, the whole construction 
of the Directive is based upon physical  goods (which might have a 
software component) placed on the market for purchase or lease. It is 
thus ill adapted to deal with the shared domain of grid-based services 
where software sold and owned by a wide range of participants in a 
grid initiative.
It  would seem therefore that  at  present the only real  way to have 
clarity  over  liability  for  possible  negative  effects  of  healthgrids  is 
through tightly constructed contracts in private law. If however the 
use  of  healthgrids  across  EU  and  international  borders  in  shared 
76  Treaty of  the European Union Art.  152 provides that  matters of  health  services organisation are 
subject to the rule of subsidiarity and limits the role of the EU to support and co-ordination.
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, A. 
Dobrev, J. Herveg, V. 
Stroetmann, K. 
Stroetmann, C. Van 
Doosselaere, P. Wilson 
 
public/private initiative is to become a reality then steps should be 
taken to develop guidelines and possibly legislation to harmonise the 
legal expectation of all actors in a healthgrid. As an interim step to EU 
legislation in this area,  it  could be suggested that  a suitable body, 
such as the High Level Group on Healthcare, is established.
However, to move healthgrids beyond the domain of university led and 
funded research tools we would need to address squarely the need to 
develop robust tools for sharing of the intellectual property inherent 
in the design and population of a healthgrid application.
As the law currently stands, the rules of copyright are very protective 
and  could  constitute  an  impediment  in  the  implementation  of 
healthgrids because they treat computer software as a copyrightable 
literary work, the same as a play or a novel. 
The owner of the copyrighted software running a healthgrid has the 
exclusive  rights  to  reproduce  his  work,  prepare  derivative  works, 
distribute copies to the public, perform the work publicly and display 
the work publicly.  Under these circumstances,  any natural  or legal 
person  would  have  to  pay  to  use  computer  programs  while  they 
constitute one of the most important compounds of healthgrids. Given 
that most Grid applications will depend on shared access to multiply 
copyrighted programmes it is unlikely that such a model of copyright 
is useful in protecting the entirety of a healthgrid application.
An open standard approach to software co-development  could help 
the development and implementation of healthgrids. The open source 
licensing  model  actually  uses  copyright  and  contract  principles  to 
retain control of the work while enabling its use effectively for free 
and could thus encourage use and development.
All  such legal  fine-tuning,  whether  through standardised contracts, 
special  data sharing agreements or open standards based software 
development will be of little use in driving forward the development 
and implementation of healthgrids if the social and economic settings 
are not  examined thoroughly in  order to develop fully  weighed up 
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cost-benefit  and  cost-utility  based  assessments  of  the  use  of 
healthgrids in healthcare delivery.
Reflecting on the Socio-Economics Section, it becomes obvious that 
the  uptake  of  healthgrid  systems  and  solutions  will  also  heavily 
depend on the extent to which they can help address problems and 
challenges of health systems. Such impact is presumed, yet there is 
little evidence of its scope. Detailed analysis of existing applications, 
as well as ex-ante assessments of the benefits from the future use of 
healthgrids will prove essential for mobilising the required will and 
enthusiasm among research funding entities,  political  organisations 
and  society  at  large.  Potential  benefits  include  time  savings, 
particularly important in cases of potential pandemics, and access to 
better quality clinical and research data leading to improvements in 
the  quality  of  clinical  outcomes.  The  methodological  framework 
developed and described above renders an adequate methodological 
framework for providing evidence on these benefits.
The same framework can also be used as the basis  for addressing 
another inhibitor to a widespread adoption of healthgrid solutions – 
lack of (knowledge about) private incentives. A business case for the 
routine use of grid technologies in the health sector is essential for 
moving  from  project-based,  exemplary  utilisation  to  a  widespread 
uptake of healthgrid-based solutions.
We  expect  that  the  evaluation  of  currently  running,  exemplary 
healthgrid  solutions  will  aid  the  design  of  the  right  incentives  for 
particular  stakeholders,  which,  facilitated  by  the  appropriate  legal 
framework, will ensure the wider adoption and uptake of healthgrid.
